Vision-Sciences, Inc.
(Exact name of Registrant as specified in its charter)

DELAWARE (State or other jurisdiction of incorporation or organization)		13-3430173 (I.R.S. Employer Identification Number)
9 Strathmore Road Natick, Massachusetts (Address of principal executive offices)		01760 (Zip Code)

Securities registered pursuant to Section 12(b) of the Act: None
Securities registered pursuant to Section 12(g) of the Act:
Common Stock, par value $.01

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No o

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ý

Indicate by check mark whether the Registrant is an accelerated filer (as defined in Exchange Act Rule 12b-2). Yes o No ý

Aggregate market value of Common Stock held by non-affiliates of the Registrant as of September 30, 2004 based upon the last sale price of the Common Stock on the Nasdaq SmallCap Market as reported by Nasdaq: $49,622,844

Number of shares outstanding of the Registrant's Common Stock as of May 31, 2005: 35,077,377

Documents incorporated by reference: Portions of the Proxy Statement for the 2005 Annual Meeting of Stockholders are incorporated by reference into Part III of this Form 10-K.

This Annual Report on Form 10-K contains forward-looking statements, including statements about new product introductions, expectations as to future sales of the products of Vision-Sciences, Inc. (the "Company", "we", "our", "us"), the availability of supplies, the sufficiency of our capital resources to meet anticipated capital requirements, our sales distribution channels and our expectations as to future expenditures, including research and development expenditures. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve risks and uncertainties, and our actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, the availability of capital resources, the availability of third-party reimbursement, government regulation, commercialization and technological difficulties, general economic conditions and other risks detailed below. See "Certain Factors That May Affect Our Future Operating Results".

This Business section should be read in conjunction with our Consolidated Financial Statements attached hereto as Appendix A, including the notes thereto.

We design, develop, manufacture and market products for endoscopy, the science of using an instrument, known as an endoscope, to provide minimally invasive access to areas not readily visible to the human eye. We operate in three reportable segments: medical, industrial and corporate.

The medical segment designs, manufactures and sells our EndoSheath® System ("EndoSheath"), a single-use device that slides on to the insertion tube of a flexible endoscope. The insertion tube is the part of an endoscope that enters the patient's body. The use of an EndoSheath gives health-care providers economic advantages because it allows them to avoid the burdensome cleaning required of endoscopes, reduces repair costs to endoscopes caused by the harsh chemicals used in the cleaning process and allows health-care providers to avoid investing in multiple endoscopes. Our EndoSheaths that have channels help to improve the practice efficiency of health-care providers by allowing them to perform procedures in their offices that otherwise they would have to perform in hospitals using special endoscopes that have channels. Often, the reimbursement rates are higher for physicians when they perform procedures in their offices. In addition, the EndoSheath is a sterile device that provides patients with a contaminant-free insertion tube for each procedure. There is a risk to patients of cross- contamination from the reuse of conventional flexible endoscopes that health-care providers are unable to effectively sterilize.

The industrial segment manufactures and repairs flexible endoscopes for the medical segment. These include our conventional nasopharyngolaryngo endoscopes, the ENT-2000 and ENT-1000, for the Ear-Nose-Throat ("ENT") market. In addition, the industrial segment manufactures and repairs our trans-nasal diagnostic esophagoscope ("TNE D scope"), our trans-nasal therapeutic esophagoscope ("TNE Bx scope"), our cystoscope ("CST-2000"), our sigmoidoscope and our bronchoscope. We expect the industrial segment will be manufacturing our other endoscopes after they complete the product development cycle. In addition, the industrial segment designs, manufactures and markets flexible endoscopes, called borescopes, for industrial markets, primarily aircraft maintenance, jet engine manufacturing and defense.

The corporate segment consists of certain administrative activities applicable to all segments.

We were incorporated in Delaware in 1987 under the name Machida Incorporated. Since that time, we have acquired by merger Cyberex Corporation (in October 1988) and Vascu-Care, Inc. (in March 1989), and acquired pursuant to a share exchange Opielab, Inc. (in September 1990). We

changed our name to Vision-Sciences, Inc. in December 1990. Our principal executive offices are located at 9 Strathmore Road, Natick, Massachusetts 01760. Our telephone number is (508) 650-9971.

Endoscopy is a minimally invasive technique that is being used with increased frequency in a growing number of medical applications. Endoscopes are used for a variety of screening and diagnostic procedures and are also used therapeutically as an alternative to more traditional surgical procedures. Endoscopic therapeutic procedures, unlike more traditional "open" surgical procedures, can be performed without a major incision, in most cases without general anesthesia, and are, therefore, safer and less expensive than traditional surgical procedures. In addition, endoscopic procedures are typically performed on an outpatient basis, generally involving less recovery time and patient discomfort than traditional surgery. The patient benefits and cost savings associated with endoscopy have caused many governmental reimbursement programs and private health insurance plans to encourage the use of endoscopic procedures in a number of medical applications. In many instances, the use of endoscopes allow physicians to receive higher reimbursement for performing procedures in their offices, compared to performing them in hospitals, due to the insurance plan not having to reimburse for the hospital cost component.

Flexible endoscopes are tubular instruments that enter the body through a natural orifice and enable physicians to view the interior of a body organ or cavity remotely and perform various screening, diagnostic and therapeutic procedures. Flexible endoscopes generally utilize fiberoptic bundles or video camera technology for image production. The physician can steer the distal portion of a flexible endoscope with control knobs on the endoscope's operator body. By maneuvering the tip of the endoscope, the physician can access body regions through lengthy and twisted passageways, and perform a variety of procedures. The typical ENT endoscope does not contain channels whereas most conventional flexible endoscopes for gastroenterology ("GI"), pulmonary, urology procedures and special ENT endoscopes do contain one or more channels that run the length of the endoscope for delivery of air, water, suction and accessory devices, such as biopsy forceps and cutting instruments.

Rigid endoscopes generally utilize a stainless steel tube encasing a series of high resolution lenses to transmit the optical image. Most rigid endoscopes do not contain the channels that are characteristic of flexible endoscopes. Rigid endoscopes are currently utilized for diagnostic and surgical procedures such as arthroscopy, laparoscopy, urological and gynecological procedures. While rigid endoscopes for other medical applications, such as bronchoscopes, sigmoidoscopes and nasopharyngo-laryngoscopes are still marketed, they have largely been supplanted by flexible endoscopes, which offer improved patient comfort and better handling capabilities. We do not currently plan to manufacture endoscopes for the rigid endoscope market.

Flexible endoscopes are widely used in hospitals, clinics and physicians' offices, primarily on an outpatient basis. Our flexible endoscopes are designed primarily for screening, diagnostic and therapeutic procedures in fields such as otolaryngology (ear-nose-throat medicine, or "ENT"), urology, gastroenterology, pulmonary medicine, primary care and surgery. We estimate, based on various industry sources, that approximately 20 million flexible endoscopic procedures in these fields are performed in the United States annually.

ENT Endoscopes. These endoscopes, typically without channels, are used for viewing the ears, nose, throat and larynx for diagnostic purposes, such as testing for throat cancer or sleep apnea. We estimate that based on industry sources, approximately 4 million such procedures are performed in the United States annually, generally by otolaryngologists and allergists in hospitals, clinics and physicians'

offices. In addition, there are ENT endoscopes with a channel, which are typically used in hospitals to perform procedures such as biopsies, removal of polyps in sinus cavities, tests for swallowing disorders and other procedures. These endoscopes require a significantly larger investment to acquire than flexible endoscopes without a channel.

Urology Endoscopes. Cystoscopes allow the urologist to view the inside of the bladder and urethra and are commonly used to diagnose and take biopsies of bladder tumors, identify obstruction of the bladder and to install and remove stents as part of surgical procedures. We estimate that based upon industry sources, over 440,000 flexible cystoscopies are performed annually in the United States, of which 79% are done in an outpatient setting. Sterile equipment is highly desired for cystoscopy, but today, most cystoscopes are disinfected, not sterilized.

Gastrointestinal Endoscopes. Based on industry sources, we estimate that over 12 million flexible endoscopic procedures involving the screening, diagnosis or treatment of the colon, esophagus, stomach and duodenum are performed in the United States annually. Continued growth in such procedures is expected to result from an increase in procedures performed for the purpose of detecting cancer of the descending colon, as well as the increased medical needs associated with an aging population. The American Cancer Society has recommended that every adult over the age of 50 (currently approximately 77 million Americans) receive a screening sigmoidoscopy every three to five years, or a colonoscopy every ten years. The most common flexible endoscopes used in GI endoscopy are sigmoidoscopes, colonoscopes, gastroscopes and duodenoscopes.

Pulmonary Endoscopes. A bronchoscope and an intubation endoscope are flexible endoscopes used for viewing the trachea, bronchi and lungs for diagnostic and therapeutic purposes, generally by pulmonary specialists and anesthesiologists in a clinic or hospital setting. We estimate that based on industry sources, approximately 500,000 procedures using flexible bronchoscopes are performed in the United States annually. Because pneumonia is common in persons infected with the HIV virus, and because bronchoscopy is often used to make this diagnosis, there has been increased usage of bronchoscopes for this purpose, as well as greater recognition of the need to perform bronchoscopies in a contamination-free manner to protect both the HIV positive patients, who have weakened immune systems, and subsequent patients on whom the bronchoscope is used.

While endoscopy represents a significant advance in the field of clinical medicine, flexible endoscopes without EndoSheaths present a number of health risks and problems to both patients and medical personnel. Flexible endoscopes are intended for repeated use in hundreds of procedures and, with each use, come in contact with some combination of the patient's blood, tissue, mucus, saliva, urine or stool. Therefore, flexible endoscopes without EndoSheaths must be meticulously manually cleaned and disinfected after each procedure. However, the design of flexible endoscopes makes it impossible to sterilize them, and even difficult to attain high-level disinfection after cleaning. As a result, the repeated use of flexible endoscopes without EndoSheaths and the difficulty of thoroughly cleaning and disinfecting them after each use create the following problems:

Difficulty of Proper Cleaning. The problems associated with cleaning flexible endoscopes used without EndoSheaths can be better understood by examining the cleaning procedures they require. The cleaning of these endoscopes is generally the responsibility of the nurse or endoscopic assistant. The Society of Gastroenterology Nurses and Associates, Inc., in 1990 published Recommended Guidelines for Infection Control in Gastrointestinal Endoscopy Settings (the "SGNA Guidelines"). Although cleaning procedures for endoscopes vary widely, the following is a summary of the principal steps in the cleaning procedures that are called for by the SGNA Guidelines:

Proper cleaning of flexible endoscopes used without EndoSheaths, even when done in compliance with the SGNA Guidelines, is difficult to achieve for a number of reasons. Firstly, the design of these flexible endoscopes, which includes channels, joints and crevices, makes it difficult to reach and clean all parts of the endoscope. As the SGNA Guidelines state, an endoscope's "complex and fragile structure presents problems in cleaning/disinfecting/sterilizing". Secondly, we believe the most important step in the cleaning process is the manual removal of organic material, and therefore, the opportunity for human error is always present, even if optimal cleaning procedures are followed. Finally, there are questions concerning the efficiency of some disinfecting agents used in the endoscope cleaning process. For example, in 1991 the federal Food & Drug Administration ("FDA") recommended that the medical profession cease the use of Sporicidin, a widely-used endoscope disinfectant, based upon the FDA's conclusion that this disinfectant does not work. The FDA has also required that the manufacturers of 2.4% glutaraldehyde-based disinfectants change the recommended soak time on their instructions for

use from 20 minutes to 45 minutes, and increase the temperature from 20 degrees Celsius to 25 degrees Celsius. This longer soak time means slower turnaround on conventional scopes, and the increased temperature of the glutaraldehyde is hazardous due to increased caustic vapors released during heating.

Health Risks. Because flexible endoscopes used without EndoSheaths are difficult to clean properly, sterilization (the complete elimination of microbial life) is virtually impossible to achieve. Therefore, "high-level disinfection" (the elimination of all microbial life other than the most highly resistant spores) is the standard currently recommended by the Centers for Disease Control ("CDC") for cleaning flexible endoscopes. However, studies indicate that high-level disinfection is often not attained and that cross-contamination remains a risk to patients and medical personnel.

Numerous infectious agents, including pseudomonas, tuberculosis and salmonella, have been reported in the medical literature as having been transmitted through the use of contaminated endoscopes. Concern about the risk of endoscopic cross-contamination has also been heightened by the increasing prevalence of the HIV and hepatitis viruses.

The cleaning procedures required for endoscopes also subject patients and medical personnel to health risks (such as severe eye, nose and throat irritation, nausea, headaches, asthma and skin rashes) from exposure to toxic disinfecting agents. The Occupational Safety and Health Administration has classified glutaraldehyde, a key ingredient in many endoscope disinfecting agents, as a highly toxic material and requires hospitals, clinics and physicians' offices to reduce the level of emissions to 0.2 parts per million wherever glutaraldehyde is used. In addition, toxic disinfectants must be disposed of in compliance with applicable environmental laws.

Other Problems. In addition to the health problems posed by the use and cleaning of conventional flexible endoscopes, the required cleaning of these products is relatively expensive, time-consuming and arduous. We estimate, based upon our own experience that the cleaning and disinfection procedure required following each use of a flexible endoscope without an EndoSheath, if done in compliance with the FDA recommendations, would take approximately 60 minutes. The repeated cleaning in harsh chemical disinfectants also subjects a flexible endoscope to wear and tear, reducing its useful life and impairing the quality of its optics. Moreover, the failure to clean all organic materials from a flexible endoscope's channels is a common cause of blocked channels, which require expensive endoscope repairs as well as a back-up inventory of endoscopes. In addition, the need to properly clean a flexible endoscope after each use requires that each doctor performing endoscopies must either have access to a number of endoscopes or be forced to wait an estimated 60 minutes between each endoscopic procedure (assuming the endoscope is cleaned in compliance with FDA Guidelines).

Our business strategy is to design, develop, manufacture and market flexible endoscopes with Slide-On EndoSheath Systems as devices that provide physicians with tools to increase their practice efficiency and also protect patients by providing a sterile insertion tube for each procedure. To implement this strategy, we developed a variety of flexible endoscopes with Slide-On EndoSheath Systems described below. We market our ENT products domestically primarily through an exclusive distribution agreement with Medtronic Xomed, Inc. We market our urology products domestically through an exclusive agreement with Medtronic USA, Inc. We market our other products domestically through our own network of independent sales representatives. We market all our products internationally through our network of independent international distributors. We manufacture EndoSheaths in our Natick, MA facility, and endoscopes in our Orangeburg, NY facility.

In the medical segment, our primary products include a family of flexible endoscopes with Slide-On EndoSheath Systems for applications in the ENT, urology, GI and pulmonary markets. In addition, through our industrial segment we currently manufacture and sell borescopes, which are endoscope devices for industrial applications, and related products.

We have developed a family of Slide-On ENT EndoSheaths for use with our own conventional ENT-2000 endoscope, our small diameter ENT-1000 endoscope and with ENT endoscopes manufactured by other companies. Slide-On EndoSheaths are made with materials using our own proprietary process that makes them slippery, allowing the health-care provider to easily slide the EndoSheath onto the insertion tube of an ENT endoscope. The user stretches the Slide-On EndoSheaths slightly until the proximal connector attaches to the strain relief of the ENT endoscope, allowing a snug fit. In addition, Slide-On ENT EndoSheaths have an optically clear window that fits securely over the ENT endoscope tip, preventing glare. After the procedure is completed, the health-care provider slides the EndoSheath off the endoscope and disposes of it. In general, ENT endoscopes do not contain air, water, suction or accessory channels, unlike endoscopes designed for use in urology, gastroenterology or pulmonology. Therefore, our standard Slide-On ENT EndoSheaths, designed to be the only component that comes into contact with the patient, do not contain channels. Other of our ENT EndoSheaths, our TNE EndoSheaths and our EndoSheaths for urology, gastroenterology and pulmonology do contain channels. We have also developed our own ENT endoscopes, with state-of-the-art fiberoptic bundles, designed so that any necessary repairs are inexpensive and with other features that we believe make them competitive with ENT endoscopes of other major manufacturers.

As part of the Slide-On family of ENT EndoSheaths, we manufacture and sell a Slide-On ENT Channeled EndoSheath and a Slide-On ENT Sensory EndoSheath, both for our own flexible ENT-2000 endoscope and for ENT endoscopes manufactured by other companies. These EndoSheaths allow physicians to perform procedures in their offices using their conventional ENT endoscopes that otherwise they would have to perform using special ENT endoscopes that contain a channel. These special ENT endoscopes are expensive and typically are found at hospitals.

The Slide-On ENT Channeled EndoSheath contains a 2.1mm channel within the Slide-On EndoSheath that the physician can use to perform biopsies or other therapeutic procedures. The Slide-On ENT Sensory EndoSheath is designed to provide ENT physicians the opportunity to perform Flexible Endoscopic Evaluation of Swallowing with Sensory Testing ("FEESST") using their conventional endoscopes. FEESST, an alternative emerging procedure to modified barium swallow studies, is performed by the ENT physician using the Slide-On ENT Sensory EndoSheath that contains a channel through which air is pulsed to the larynx to elicit an airway protective reflex. The ENT physician, by observing the reaction to the air pulse, is able to diagnose, treat and manage patients with swallowing disorders with an emphasis on decreasing the risk of choking, coughing and aspirating food and liquids that can lead to aspiration pneumonia. Both of these EndoSheaths enhance the practice efficiency of physicians, as they enable the physicians to use their conventional ENT endoscope to perform tests in their offices, compared to traveling to a hospital to perform them with a special ENT endoscope. Often, by performing the tests in their offices, the ENT physician receives a higher reimbursement, compared to the reimbursement received when the test is performed in a hospital.

We manufacture and sell a TNE D scope with Slide-On EndoSheath System that is designed to allow ENT and GI physicians to view the esophagus transnasally, i.e. through the nose, compared to viewing it transorally, i.e. through the mouth, as with a conventional gastroscope. Conventional

gastroscopes require patients to be consciously sedated to counteract the gag reflex encountered when a gastroscope is inserted transorally. Our TNE D scope with Slide-On EndoSheath System, with its narrow diameter allowing transnasal passage, enables physicians to perform examinations in their office of a patient's throat and esophagus for manifestations of gastroesophageal reflux disease ("GERD"). We estimate that approximately 40 million people in the United States suffer from some form of GERD affecting their vocal chords, esophagus or stomach.

The TNE D scope can also be used to evaluate patients with dysphagia, a condition broadly defined as a subjective or objective patient complaint of difficulty swallowing, or of coughing or choking while swallowing or eating. A physician performs this test if an oropharyngeal exam did not fully reveal the cause of the patient's swallowing problem. Currently this procedure is performed in a hospital setting with conscious sedation and a special endoscope that contains a biopsy channel that doubles as an air-administration channel. The TNE D scope with Slide-On EndoSheath System is designed to allow these tests to be done by ENT and GI physicians in their offices, thus improving practice efficiency and lowering overall costs to the health care system. Both the diagnostic and therapeutic procedures have reimbursement codes, allowing physicians to receive payment for the service, and allowing us to measure the practice efficiencies presented by our products. We completed the development of the TNE D scope with Slide-On EndoSheath System in our fiscal year ended March 31, 2004 ("FY 04").

In our fiscal year ended March 31, 2005 ("FY 05"), we received clearance from the FDA to market our TNE Bx flexible trans-nasal endoscope with Slide-On EndoSheath System. The TNE Bx is designed to allow ENT and GI physicians to view the esophagus transnasally, and to perform therapeutic procedures, such as biopsies, in an office setting.

We have developed a cystoscope (the "CST-2000") with Slide-On EndoSheath System for use by urologists. In April 2004, we received clearance from the FDA to market the CST-2000 with Slide-On EndoSheath System. The CST-2000 with Slide-On EndoSheath consists of two components—a reusable flexible endoscope incorporating our proprietary design, and a proprietary, sterile, disposable EndoSheath—functional when used together. The EndoSheath slides easily onto the insertion tube of the CST-2000, and contains a 2.1 millimeter channel for irrigation, air and suction capabilities. The EndoSheath is the only component that comes into contact with the patient, and is disposed of after each procedure. This allows the physician to avoid using harsh chemicals to reprocess the endoscope after each use. Avoiding these reprocessing steps allows the physician to increase the number of patients who can be examined in a given day. This improves the physician's practice efficiency, while also ensuring a sterile insertion tube for each patient. In April 2004, CIDEX® OPA Solution, a common disinfectant used to reprocess cystoscopes, was contraindicated for the reprocessing of urological instruments that were to be used on patients with a history of bladder cancer. This was due to instances of allergic reactions to that disinfectant by patients who had undergone repeated cystoscopies. Using the EndoSheath also reduces the wear and tear on the CST-2000, further reducing costs of the physician's practice.

We have developed a family of proprietary flexible endoscope systems for GI and pulmonary applications consisting of two main components—a reusable flexible endoscope incorporating our proprietary design, and a proprietary, sterile, disposable EndoSheath. The EndoSheaths and endoscopes included in these systems are functional only when used together.

Under the Machida name, we design, manufacture and market flexible borescopes, which are similar in design to endoscopes and are used for inspection and quality-control functions in industrial applications, such as the inspection of aircraft engines and nuclear power plants. Through Machida, we were first to offer a flexible borescope with a grinding attachment that allows users to "blend", or smooth, small cracks in small turbine blades of jet engines without disassembling the engine, which would involve significant expense and delay. We also offer a variety of ancillary products for use with flexible endoscopes and borescopes, such as light sources, cameras, adapters, accessories and imaging systems.

The end users of our disposable EndoSheaths, flexible endoscopes and related products are otolaryngologists (ENT doctors), urologists, gastroenterologists, pulmonologists and primary care physicians in hospitals, medical clinics and physicians' offices. As of May 1, 2005, we had five sales and marketing employees. Since September 19, 2003 we have been distributing all of our products for the ENT markets in the U.S.A. and Canada through Medtronic Xomed, Inc. ("Medtronic Xomed") as part of our exclusive distribution agreement (the "Medtronic Agreement") with them. Since December 2004, we have been distributing all of our products for the urology markets in the U.S.A. and Canada through Medtronic USA, Inc. ("MGU") as part of our exclusive distribution agreement (the "MGU Agreement") with them. We have retained our domestic network of independent sales representatives for the GI and pulmonary product lines. We distribute all our products internationally through 29 independent international distributors in Europe, Australia, the Middle East and the Far East. We periodically evaluate the effectiveness of our sales channels, and may change them if we believe a different method will increase our revenues.

Although we have no specific plans or commitments in this regard, we may also license to one or more third parties rights to manufacture and sell reusable flexible endoscopes incorporating our proprietary design features, while retaining the rights to manufacture and sell the EndoSheaths used with these endoscopes.

Our borescopes are sold both directly by our Machida subsidiary and through independent sales representatives.

Sales to unaffiliated customers outside of the United States were approximately $2,090,000, $2,981,000 and $3,370,000 for the fiscal year ended March 31, 2003 ("FY 03"), FY 04 and FY 05, respectively. In FY 05, sales to foreign customers accounted for approximately 38% of the annual net sales of our medical segment and 19% of net annual sales of our industrial segment. In FY 04, sales to foreign customers accounted for approximately 34% of the annual net sales of our medical segment and 21% of net annual sales of our industrial segment. We expect to sell our medical segment products outside of the United States in the fiscal year ending March 31, 2006 ("FY 06") in a higher proportion than in FY 05, due primarily to planned higher sales of ENT and urology products to our current distributor network, and to planned expansion of our distributor network to countries we do not currently have a presence. However, there can be no assurance that we will meet our goals. Finding international distributors with the desired skills, market knowledge and financial capabilities can be a difficult process and take considerable time to accomplish. We currently sell certain models of our borescopes and repair services outside of the United States.

During FY 03, no customer accounted for over 10% of net sales. During FY 04, Medtronic Xomed and Gyrus International Ltd. accounted for 30% and 10% of net sales, respectively. During FY 05, Medtronic Xomed accounted for 35% of net sales.

We had an order backlog of approximately $1,118,000 at March 31, 2005, compared to a backlog of approximately $1,797,000 at March 31, 2004. The backlog in 2005 was comprised of approximately $979,000 and $139,000 for the medical and industrial segments, respectively, compared to approximately $1,585,000 and $212,000 for those same segments at March 31 2004. The decrease in the medical segment backlog is primarily due to a decrease in ENT endoscopes and ENT EndoSheaths for delivery to Medtronic Xomed. The decrease in the backlog of the industrial segment was due primarily to a decrease in the amount of orders from that segment's existing customer base. We expect to fill over 75% of our order backlog in FY 06.

We produce EndoSheaths at our Natick, Massachusetts facility using raw materials, molded parts and components purchased from independent vendors, some of which are manufactured to our specifications. We manufacture our ENT EndoSheaths using proprietary processes that utilize the forming and bonding machines that were manufactured to our specifications. In addition, we use molded purchased parts and a worldwide, royalty-free exclusive license, negotiated with a third party, to manufacture optically clear windows. This license is for windows used in our EndoSheaths for ENT and intubation endoscopes. We have also negotiated a non-exclusive license to include the same technology in our EndoSheaths for use in other markets. Currently, we are using this technology in the EndoSheaths for the urology and pulmonary markets.

We assemble the GI and pulmonary EndoSheaths using molded and extruded components purchased from independent vendors, some of which are manufactured to our specifications. Most purchased components are available from multiple sources. With the exception of our supply agreement with Pentax Corporation ("Pentax"), discussed below, we have no long-term agreements with any of our vendors or suppliers, and we purchase our required components and supplies on a purchase-order basis. We contract with third parties for the sterilization of all of our EndoSheaths.

In June 2003, we entered into a Contract Manufacturing Agreement, a Loan Agreement and a Pledge Agreement (collectively, the "3BY Agreements") with Three BY Ltd., an Israeli company ("3BY"). The purpose of the 3BY Agreements was to lower the manufacturing cost of our EndoSheath products, and to provide for increased manufacturing capacity of our ENT EndoSheaths. The 3BY Agreements provide for, among other things, the manufacture of certain of our products by 3BY, and a loan of up to $267,500 from us to 3BY for the purchase and installation of certain manufacturing equipment by 3BY, at 3BY's facility, to be used to manufacture certain of our products. As of December 31, 2003, we had advanced $267,500 to 3BY. During FY 05 it became apparent we would not be producing the quantity of ENT EndoSheaths that we had anticipated, increasing the risk associated with the repayment of the advance. To eliminate this risk and secure title to the equipment, we took ownership of the equipment, as provided for in the Loan Agreement, effective October 1, 2004.

We received production from 3BY from September 30, 2004 through March 31, 2005. In May 2005, we realized that this transition was not going to be as successful as we had planned, due to a variety of issues surrounding quality, consistency of personnel and cost. As a result, we have decided to bring the manufacture of all EndoSheaths back to our facility in Natick MA. We expect to complete this move back during the second fiscal quarter ending September 30, 2005.

We assemble our flexible endoscopes for the medical and industrial segments at our Orangeburg, New York facility using purchased components and subassemblies, as well as certain proprietary components produced by us. Most purchased components and subassemblies are available from more than one supplier. However, certain critical components, such as image bundles for all endoscopes manufactured for the medical segment and operator control bodies for sigmoidoscopes, are currently being purchased solely from Pentax, who competes with our medical segment in the endoscope market. These components are being purchased pursuant to a supply agreement, which expired in March 2005. We are currently in the process of renewing this agreement, and do not anticipate any terms that will be significantly different from the current terms. We believe that while substitute components, which are currently produced by sources other than Pentax, would be available, such substitute components may be more expensive and of a lower quality and may require a redesign of our endoscope and additional regulatory clearances. Moreover, such substitute components may not be immediately available in quantities needed by us. Our inability to obtain a sufficient quantity of such critical components on favorable terms could materially adversely affect our business. To date, we have encountered no significant difficulties or delays in obtaining a sufficient quantity of such critical components or subassemblies for our medical endoscopes. However, there can be no assurance that no difficulties or delays will be experienced in the future as we increase our manufacturing operations. The industrial segment purchased approximately $1,867,000 and $1,477,000 worth of products, for the manufacture of both medical and industrial products, from Pentax in FY 05 and FY 04, respectively. See "Certain Factors That May Affect Our Future Operating Results."

Our borescopes are assembled using components and subassemblies purchased from independent vendors. While most components and subassemblies are currently available from more than one supplier, certain critical components are currently purchased only from Machida Endoscope Company, Ltd., an unaffiliated Japanese company. The failure of us to obtain a sufficient quantity of such components on favorable terms could materially adversely affect our business. See "Certain Factors That May Affect Our Future Operating Results."

We purchase light sources, cameras, adapters, accessories and imaging systems for industrial applications from a variety of vendors.

We believe that the primary competitive factors in the medical market for flexible endoscopes and EndoSheaths are the safety and effectiveness (including optical quality) of the products offered, ease of product use, product reliability, price, physician familiarity with the manufacturer and its products and third-party reimbursement policies. In our industrial markets, we believe that product effectiveness, ease of product use, product reliability and price are the principal competitive factors. Our ability to compete in our markets is affected by our product development and innovation capabilities, our ability to obtain required regulatory clearances, our ability to protect the proprietary technology included in its products, our manufacturing and marketing skills and our ability to attract and retain skilled employees.

The flexible endoscopes and related products currently sold and under development by us face competition primarily from medical products companies such as Olympus and Pentax. In addition, any company that is able to significantly redesign conventional flexible endoscopes to simplify the disinfection process, or significantly improve the current methods of disinfecting flexible endoscopes, would provide competition for our products. The principal competitors for our industrial products are Olympus and Welch Allyn, Inc. In FY 06 a competing manufacturer of EndoSheaths emerged in the European market. We believe this competitor is selling products with features that are within the claims of our patents. We are defending, and intend to continue to defend, our intellectual property rights vigorously. We believe our product quality, breadth of product offerings and financial resources are superior to that competitor's.

Our competitors and some potential competitors have greater financial resources, research and development personnel and manufacturing and marketing capabilities than we do. In addition, it is possible that other large health care companies may enter the flexible endoscope market in the future.

Our success depends in part on our ability to maintain patent protection for our products, to preserve our trade secrets and to operate without infringing the proprietary rights of third parties. Our strategy regarding the protection of proprietary rights and innovations is to seek patents on those portions of our technology that we believe are patentable, and to protect as trade secrets other confidential and proprietary information.

We, along with our subsidiaries, currently hold 29 U.S. patents and have 9 U.S. patent applications pending. In addition, we have 20 foreign patents and have 17 foreign patent applications pending. All of these patents relate to our disposable EndoSheaths and reusable flexible endoscopes. The issued patents will expire on various dates in the years 2008 through 2022. In addition to those listed above, we have 2 U.S. patents issued and 5 U.S. patents pending in the U.S. and 12 corresponding foreign applications for Complementary Metal Oxide Semiconductor ("CMOS") image sensor design patents. There can be no assurance that our pending patent applications will result in patents being issued or that our competitors will not circumvent, or challenge the validity of, any patents issued to us. In addition, in the event that another party infringes our patent rights, the enforcement of such rights is at our option and can be a lengthy and costly process, with no guarantee of success.

Some of the technology used in, and that may be important to, our products is not covered by any patent or patent application. We seek to maintain the confidentiality of our proprietary technology by requiring all employees who work with proprietary information to sign confidentiality agreements and by limiting access by outside parties to such confidential information. However, there can be no assurance that these measures will prevent the unauthorized disclosure or use of this information, or that others will not be able to independently develop such information. Moreover, as is the case with our patent rights, the enforcement of our trade secret rights can be lengthy and costly, with no guarantee of success.

To date, no claims have been brought against us alleging that our technology or products infringe any intellectual property rights of others. However, there can be no assurance that such claims will not be brought against us in the future or that any such claims will not be successful.

The medical products that we currently market and that are under development are regulated as medical devices by the FDA under the federal Food, Drug and Cosmetic Act (the "FDC Act") and require regulatory clearance prior to commercialization in the United States. Under the FDC Act, the FDA regulates clinical testing, manufacturing, labeling, distribution and promotion of medical devices in the United States. Various states and other countries in which our products may be sold in the future may impose additional regulatory requirements.

Following the enactment of the Medical Device Amendments to the FDC Act in May 1976, the FDA classified medical devices in commercial distribution into one of three classes, Class I, II, or III. This classification is based on the controls necessary to reasonably ensure the safety and effectiveness of the medical device. Class I devices are those devices whose safety and effectiveness can reasonably be ensured through general controls, such as adequate labeling, pre-market notification, and adherence to the FDA's Quality System Regulations ("QSR"). Some Class I devices are further exempted from some of the general controls. Class II devices are those devices whose safety and effectiveness can reasonably be ensured through the use of special controls, such as performance standards, post-market surveillance, patient registries and FDA guidelines. Class III devices are devices that must receive

pre-market approval by the FDA to ensure their safety and effectiveness. Generally, Class III devices are limited to life-sustaining, life-supporting or implantable devices.

If a manufacturer or distributor of medical devices can establish that a new device is "substantially equivalent" to a legally marketed Class I or Class II medical device or to a Class III medical device for which the FDA has not required pre-market approval, the manufacturer or distributor may seek FDA marketing clearance for the device by filing a 510(k) Pre-market Notification. The 510(k) Pre-market Notification and the claim of substantial equivalence may have to be supported by various types of information indicating that the device is as safe and effective for its intended use as a legally marketed predicate device.

Following submission of the 510(k) Pre-market Notification, the manufacturer or distributor may not place the device into commercial distribution until an order is issued by the FDA. By regulation, the FDA has no specific time limit by which it must respond to a 510(k) Pre-market Notification. At this time, the FDA typically responds to the submission of a 510(k) Pre-market Notification within approximately 90 days. The FDA may declare that the device is "substantially equivalent" to another legally marketed device and allow the proposed device to be marketed in the United States. The FDA may, however, determine that the proposed device is not substantially equivalent, or may require further information, such as additional test data, before the FDA is able to make a determination regarding substantial equivalence. Such determination or request for additional information could delay the market introduction of our products and could have a material adverse effect on us.

Flexible endoscopes, EndoSheaths, and accessory products have been classified by the FDA as Class II devices, and a Section 510(k) Pre-market Notification must be submitted to and cleared by the FDA before such devices can be sold. We have received FDA clearance of our 510(k) Pre-market Notifications for all of our products that require clearance. We expect that we will be required to obtain 510(k) clearance for each additional disposable EndoSheath/reusable flexible endoscope system that we develop in the future.

Effective July 1998, our Natick, Massachusetts facility was certified as having established, and we continue to maintain, a quality system that meets the requirements of ISO 9001 and EN 46001. In addition, the certification confirmed conformance to the essential requirements of the Council Directive 93/42/EEC, and application of this system at every stage from initial design controls to final product release to distribution. The Orangeburg, NY facility falls under the Natick quality system, and is audited by members of the Natick Quality Assurance department. In July 2004, our Natick quality system was re-certified for continued conformance to ISO 9001, EN 46001 and ISO 13485. In addition to the three-year certification audits, we undergo annual surveillance audits to confirm that we are maintaining our quality system. The Natick and Orangeburg facilities are registered with the FDA as medical device manufacturers. As a result, these facilities are subject to the FDA's QSR, which regulate their design, manufacturing, testing, quality control and documentation procedures. We are also required to comply with the FDA's labeling requirements, as well as its information reporting regulations. The export of medical devices is also subject to regulation in certain instances. Our compliance with these various regulatory requirements will be monitored through periodic inspections by the FDA and audits by independent authorities to maintain our ISO 9001 and ISO 13485 status. 3BY is certified as meeting the standards of ISO 9001 and ISO 13485, and is registered with the FDA as a contract manufacturer.

The process of obtaining required regulatory clearances can be lengthy and expensive, and compliance with ISO 9001 and the FDA's QSR and regulatory requirements can be burdensome. Moreover, there can be no assurance that the required regulatory clearances will be obtained, and those obtained may include significant limitations on the uses of the product in question. In addition, changes in existing regulations or the adoption of new regulations could make regulatory compliance by us more difficult in the future. The failure to obtain the required regulatory clearances or to comply

with applicable regulations may result in fines, delays or suspensions of clearances, seizures, recalls of products, operating restrictions or criminal prosecutions, and could have a material adverse effect on our operations.

Hospitals, medical clinics and physicians' offices that purchase medical devices such as our EndoSheaths and flexible endoscopes generally rely on third-party payors, such as Medicare, Medicaid and private health insurance plans to pay for some or all of the costs of the screening, diagnostic and therapeutic procedures performed with these devices. Whether a particular procedure qualifies for third-party reimbursement depends upon such factors as the safety and effectiveness of the procedure, and reimbursement may be denied if the medical device used is experimental or was used for a non-approved indication. We believe, based upon our knowledge of third-party reimbursement practices, advice from consultants in this area and our own selling experience, that third-party reimbursement is available for most procedures that utilize our products. However, not all third-party payors will reimburse health-care providers separately for the cost of our EndoSheath.

Third-party payors use a variety of mechanisms to determine reimbursement amounts for procedures such as endoscopies. In most cases, payment is based upon amounts determined by the Centers for Medicare & Medicaid Services ("CMS"), a governmental agency under the U.S. Department of Health and Human Services. As part of its responsibilities, CMS assigns relative value units ("RVUs") to over 10,000 physician services. An RVU for a specific procedure is comprised of values for work, practice expense and malpractice insurance, and when multiplied by a Conversion Factor, represents a dollar value for a specific procedure.

CMS has multiple fee schedules to accommodate payment to the hospital, the ambulatory surgery center ("ASC") and the physician. Physician services are reimbursed based on where the service is performed. If the physician performs the service in his or her office and the office bears the burden of overhead costs, the physician is reimbursed based on non-facility relative value units to accommodate the overhead costs. If the physician performs the service within a hospital or ASC, the payment is lower, reflecting the physician work and malpractice expenses, but without the overhead since the facility bears that financial burden. Based upon a review of calendar year 2005 fee schedules for the hospital outpatient and physician payment for procedures that utilize our ENT EndoSheath, ENT Channeled EndoSheath, ENT Sensory EndoSheath, our TNE D EndoSheath and our TNE Bx EndoSheath, physicians will receive between 49% and 154% more by performing procedures in their offices, than if they performed those procedures in hospitals. For a diagnostic cystoscopy, the physician will receive 87% more by doing the procedure in his or her office, than if they performed that procedure in the hospital.

We believe that, based upon the resource-based practice expense RVU, the number of procedures performed in non-facility settings will increase. This increase will be due primarily to the increased differential in payments that physicians will receive for performing these procedures. As these procedures move to non-facility settings, physicians will have to contend with the cost and effort required to reprocess endoscopes. We believe our disposable EndoSheaths, which eliminate the time and cost of cleaning endoscopes, will provide an economically beneficial alternative to the use of endoscopes without EndoSheaths. This economic benefit is based upon the provider not having to purchase multiple endoscopes, expensive special endoscopes with channels and expensive sterilizing equipment and supplies as well as not having to spend valuable time cleaning endoscopes. In addition, we believe that with approximately 77 million people in the United States over the age of 50, there will be an increase in the potential number of procedures that physicians will be performing. We believe our disposable EndoSheaths combined with the resource-based system for setting values for physician services together represent a sound economic solution for performing diagnostic and therapeutic procedures for a variety of illnesses.

There can be no assurance that third-party reimbursement will continue to be available for procedures performed with our products or that the cost of our EndoSheaths would be covered by such reimbursement in the future. In addition, reimbursement standards and rates may change. We believe that the inability of users of our GI and pulmonary EndoSheaths to obtain adequate reimbursement from third-party payors has had a materially adverse effect on us.

The nature of our products exposes the Company to significant product liability risks. We maintain product liability insurance with coverage limits of $2,000,000 per year. We believe that this level of coverage is adequate, given our past sales levels and our anticipated sales levels for FY 06. We evaluate the adequacy of this coverage annually to determine if we need to increase it. No product liability claims have been brought against us to date. However, there can be no assurance that product liability insurance will continue to be available to us on acceptable terms, or that product liability claims in excess of our insurance coverage, if any, will not be successfully asserted against us in the future.

We believe that our future success depends in part upon our ability to develop new products and enhance our existing products. In the past, we have devoted significant resources to research and development.

Our research and development expenses, excluding stock-based compensation charges and credits, in FY 03, FY 04 and FY 05 were approximately $426,000, $689,000 and $1,422,000, respectively. When non-cash stock-based compensation charges and credits are included, our research and development expenses in FY 03, FY 04 and FY 05 were approximately $236,000, $3,272,000 and $1,422,000, respectively.

In FY 03, our research and development efforts focused on finishing the Slide-On bronchoscope EndoSheath and the ENT Slide-On Channeled EndoSheath, and beginning the development efforts for the ENT Slide-On Sensory EndoSheath and the TNE D endoscope with Slide-On EndoSheath. In FY 04, our research and development efforts focused on completing products for the ENT Slide-On Sensory EndoSheath and the TNE D endoscope with Slide-On EndoSheath. In addition, we completed the development of our ENT-1000 small diameter endoscope with Slide-On EndoSheath System. In FY 05, our research and development efforts focused on the introduction of our TNE Bx and cystoscopes, each with Slide-On EndoSheaths. The ENT Slide-On Channeled EndoSheath, the ENT Slide-On Sensory EndoSheath, the TNE D and TNE Bx endoscopes and their Slide-On EndoSheaths are all marketed and sold to physicians in the ENT market by Medtronic Xomed, our exclusive distributor for these products in the U.S.A. and Canada. Our cystoscope with Slide-On EndoSheath are marketed and sold by MGU to urologists in the U.S.A. and Canada. We also market all these products internationally through our network of independent distributors. In FY 05, we generated 20% of our medical segment sales from the new TNE D, TNE Bx and cystoscope endoscopes and Slide-On EndoSheaths.

In FY 06, our research and development plans include the release of a portable ENT-3000 endoscope with battery powered LED light source, a new line of videoscopes, a new low cost EndoSheath suitable for high volume production and design improvements that will allow us to reduce the manufacturing costs of our EndoSheaths for the TNE D, TNE Bx and cystoscope products. In May 2005, we received clearance from the FDA to market the ENT-3000 endoscope. We believe all these products will prove useful to increase the practice efficiency of physicians, and provide for patient safety.

As of April 30, 2005, the Company had 77 employees, including temporary employees. No Company employees are represented by a labor union. The Company believes that its employee relations are good. The Company's success depends in large part upon its ability to attract and retain highly qualified scientific, management, sales and marketing personnel.

Ron Hadani, age 48, has been our President and Chief Executive Officer since February 2003. From 2001 to February 1, 2003, Mr. Hadani was a self-employed consultant, working in various capacities with early-stage companies in the U.S and Israel. From 1999-2001, he served as President of Kontran Medical, LLC. From 1997-1999 he served as Divisional Vice President of U.S. Surgical, a division of Tyco International, Ltd.

Katsumi Oneda, age 67, a co-founder of the Company, was President and Chief Executive Officer from October 1993 to February 2003, and has served as Chairman of the Board of Directors since October 1993. He served as Vice-Chairman of the Board of Directors of the Company from May 1992 to October 1993, as Honorary Chairman of the Board of Directors from October 1991 to October 1993, and as Chairman of the Board of Directors from September 1990 to October 1991. Mr. Oneda is a director of several private companies. He has been a director since 1987, and is a member of the Executive Committee.

Lewis C. Pell, age 62, a co-founder of the Company, has been Vice-Chairman of the Board of Directors since May 1992, and is a member of the Executive Committee. Mr. Pell has served as a director of Heart Technology, Inc., a publicly-held medical device company. Mr. Pell is a founder, or co-founder, and a director of a number of other privately-held medical device companies.

James A. Tracy, age 56, joined the Company in July 1997 and was elected Vice President Finance in August 1997. From 1994 to 1996 Mr. Tracy was the Vice President Finance at ORS Environmental Systems, a manufacturer of environmental equipment and sensor instrumentation. He received a CPA certificate in 1975.

Mark S. Landman, age 51, has served as Vice President Operations of the medical segment since July 1999. Mr. Landman joined the Company in January 1991, and served in a variety of roles in product development, project management, manufacturing engineering and material control from that date to July 1999.

Jitendra Patel, age 52, has served as Vice President Sales and Marketing of the industrial segment since August 2000. From August 1995 to July 2000, he served as the Manager of Sales and Marketing for that segment.

Gerald D. Erb, age 53, has served as Vice President Marketing and Sales for the medical segment since September 27, 2004. From 2001 to September 2004, Mr. Erb served as principal of Erb Associates, a strategic consulting practice for medical services, information technology and imaging device companies. From 1998 to 2000, Mr. Erb served as the Chief Executive Officer of Secure Archive, Inc., a cardiology information technology software company.

Kenneth A. Spector, age 53, has served as Vice President Research & Development for both the medical and industrial segments since September 27, 2004. From 2000 to September 2004, Mr. Spector served as a principal at Kasal Consulting, a consulting practice dedicated to developing new products for the medical device industry. From 1998 to 2000, Mr. Spector served as the Vice President Research & Development for Cortek, Inc., a start-up company that developed medical devices for the spinal fusion market.

Officers are elected on an annual basis and serve at the discretion of the Board of Directors.

The operations of our medical segment currently occupy approximately 20,000 square feet of space in Natick, Massachusetts under a lease that expires in October 2006. The operations of the Company's industrial segment, and the offices of the Company's corporate segment are located in Orangeburg, New York under a lease for approximately 10,000 square feet, which expires in August 2010, and a sublease for approximately 5,000 square feet, which expires in July 2005. The Company expects to renew the sublease for a twelve-month period ending July 2006.

Our Natick and Orangeburg facilities are registered with the FDA as medical device manufacturing facilities and, therefore, are subject to the FDA's QSR regarding manufacturing, testing, quality control and documentation procedures. We believe that the physical characteristics and layouts of these facilities are adequate to manufacture our products in compliance with applicable FDA regulations. In addition, our Natick facility is registered as meeting the requirements of ISO 9001, EN 46001 and ISO 13485, allowing us to sell our medical products in Europe and Canada.

As of March 31, 2005, there were no material legal proceedings to which we or any of our subsidiaries are a party, or to which any of our properties are subject.

No matters were submitted to a vote of our security holders during the last quarter of FY 05.

Item 5. Market for the Registrant's Common Stock and Related Stockholder Matters

Since October 30, 1997, the Company's Common Stock has been quoted on the Nasdaq SmallCap Market under the symbol VSCI. The following table sets forth the high and low sale prices for the Common Stock on the Nasdaq SmallCap Market, as reported by Nasdaq during the periods indicated.

Fiscal Year Ended March 31, 2004	High		Low
1st Quarter	$	1.41	$	.86
2nd Quarter		2.40		1.05
3rd Quarter		2.10		1.35
4th Quarter		3.90		1.56

Fiscal Year Ended March 31, 2005	High		Low
1st Quarter	$	5.20	$	3.12
2nd Quarter		4.32		2.57
3rd Quarter		3.80		1.90
4th Quarter		4.00		2.70

Such over-the-counter market quotations reflect inter-dealer prices without retail mark-up, mark-down, or commission and may not necessarily represent actual transactions.

As of June 6, 2005, there were 35,077,377 outstanding shares of Common Stock held by 206 stockholders of record, in addition to which there were approximately 1700 beneficial stockholders.

We have never paid cash dividends on our Common Stock, and we do not expect to pay any cash dividends on our Common Stock in the foreseeable future. In accordance with a line-of-credit agreement that we have with a bank, we are prevented from paying cash dividends on our Common Stock.

In March 2003, we completed a private equity placement with two stockholders, who are also directors and employees of the Company (the "Insiders"), in an offering exempt from registration under Section 4(2) of the Securities Act of 1933, as amended. We sold an aggregate of 2,385,568 shares of common stock at a price of $.67 per share, which represented 67% of the average closing price of the common stock on the Nasdaq SmallCap Market during the five trading days ended March 21, 2003. We received an aggregate consideration of approximately $1,600,000 for the newly issued shares of Common Stock. In April, 2003, we completed a private equity placement with accredited private investors in an offering exempt from registration under Section 4(2) of the Securities Act of 1933, as amended. We sold an aggregate of 524,098 shares of common stock at a price of $0.67 per share, which represented 67% of the average closing price of the common stock on the Nasdaq SmallCap Market during the five trading days ended March 21, 2003. We received an aggregate consideration of approximately $351,000 for the newly issued shares of Common Stock. These two placements were considered one transaction that was determined to be at fair market value based upon a review by the Company's Board of Directors of the daily volume of trading of the Company's common stock on the Nasdaq SmallCap market, and based upon the fact that there was no requirement for registering the shares. The transaction was approved by the Company's Board of Directors by a unanimous written consent.

the Company, acquired approximately $8,000,000 of the common stock sold, and the Insiders acquired the remainder. In addition, as part of the transaction, the Company issued warrants to purchase an additional 1,103,704 shares of common stock to the investors and to the placement agent. The warrants are exercisable immediately over a period of five years at a price of $3.75 per share. The agreement does not require the Company to file any registration statement covering the resale of any of the common stock or warrants acquired by the investors in the transaction. However, the agreement does provide the investors with piggyback registration rights when and if the Company does file a registration statement. The transaction was determined to be at fair market value based upon a review by the Board of Directors of the daily volume of trading of the Company's common stock on the Nasdaq SmallCap, and based upon the fact that there was no requirement for registering the shares. The transaction was approved by the Company's Board of Directors in a unanimous written consent.

On March 30, 2005, in response to the Nasdaq Stock Market informing the Company that it was in violation of certain Nasdaq Marketplace Rules regarding the sale on February 14, 2005 of common stock to officers and directors at less than the closing bid price of the common stock, the Company and the Insiders executed separate agreements to remediate the violation. One of the Insiders executed a contribution agreement providing for the payment of an additional amount in respect of the common stock purchased from the Company on February 14, 2005, thus bringing the price paid by him to $2.95 per share, the closing bid price of the common stock on February 14, 2005. The other Insider executed a rescission agreement, agreeing to rescind 31,387 shares of common stock purchased by him on February 14, 2005, thus increasing the cash price paid by him for the remaining shares to $2.95 per share. The Company recorded the contribution, received on April 7, 2005, as a subscription receivable and additional-paid-in-capital as of March 31, 2005. The Company recorded the rescission as a change in outstanding shares as of March 31, 2005.

The following table provides information about the securities authorized for issuance under our equity compensation plans as of March 31, 2005:

There were no repurchases of registered equity securities during the last quarter of FY 05.

The following table summarizes certain selected financial data and should be read in conjunction with the financial statements and related notes contained in Appendix A to this report.

In November 2004, the FASB issued SFAS No. 151, Inventory Costs, amendment to ARB No. 43, Chapter 4, (SFAS 151). SFAS 151 amends the guidance in ARB No. 43, Chapter 4, "Inventory Pricing", to clarify the accounting for abnormal amounts of idle facility expense, freight, handling costs and wasted material (spoilage). Among other provisions, the new rule requires that items such as idle facility expense, excessive spoilage, double freight and rehandling costs be recognized as current period charges regardless of whether they meet the criterion of "so abnormal" as stated in ARB No. 43. Additionally, SFAS 151 requires that the allocation of fixed production overheads to the costs of conversion be based upon the normal capacity of the production facilities. SFAS 151 is effective for fiscal years beginning after June 15, 2005. The Company is currently evaluating the effect that the adoption of SFAS 151 will have on its consolidated results of operations and financial condition but does not expect SFAS 151 to have a material impact.

In December 2004, the FASB issued SFAS No. 123 (revised 2004), Share-Based Payment (SFAS 123R). SFAS 123R is a revision of SFAS No. 123, Accounting for Stock-Based Compensation and supersedes APB No. 25, Accounting for Stock Issued to Employees, and its related implementation guidance. SFAS 123R requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values beginning with the first interim or annual period after June 15, 2005, with early adoption encouraged. The pro forma disclosures previously permitted under SFAS 123 no longer will be an alternative to financial statement recognition. The Company is required to adopt SFAS 123R in the first quarter of fiscal 2007, beginning April 1, 2006. Under SFAS 123R, the Company must determine the appropriate fair value model to be used for valuing share-based payments, the amortization method for compensation costs and the transition method to be used at date of adoption. The transition methods include prospective and retrospective adoption options. Under the retroactive option, prior periods may be restated either as of the beginning of the year of adoption or for all periods presented. The prospective method requires that compensation expense be recorded for all unvested stock options and restricted stock over the

remaining vesting period beginning in the first quarter of adoption of SFAS 123R, while the retroactive method would record compensation expense for all unvested stock options and restricted stock beginning with the first period restated. The Company is evaluating the requirements of SFAS 123R and expects that the adoption of SFAS 123R may have a material impact on its consolidated results of operations and earnings per share. The Company has not yet determined the method of adoption or the effect of adopting SFAS 123R, and it has not determined whether the adoption will result in amounts that are similar to the current pro forma disclosures under SFAS 123.

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

This Annual Report on Form 10-K contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements include statements about expectations about future financial results, future products and future sales of new and existing products, future expenditures, and capital resources to meet anticipated requirements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve risks and uncertainties, and our actual results may differ significantly from those discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to, the availability of capital resources, the availability of third-party reimbursement, government regulation, the availability of supplies, competition, technological difficulties, general economic conditions and other risks detailed in our most recent Annual Report on Form 10-K and any subsequent periodic filings made with the Securities and Exchange Commission. We do not undertake an obligation to update our forward-looking statements to reflect future events or circumstances.

We develop, manufacture and sell flexible endoscope products for the medical device and industrial device markets. We operate in three reporting segments: medical, industrial and corporate.

The medical segment supplies flexible endoscopes and disposable EndoSheaths to the ENT, urology, GI and pulmonary markets. Health-care providers use EndoSheaths to cover the insertion tube of flexible endoscopes, such as ENT endoscopes, TNE endoscopes, cystoscopes, sigmoidoscopes and bronchoscopes. The EndoSheaths allow the health-care providers to process patients economically by avoiding the reprocessing of endoscopes after each use. In addition, the EndoSheaths ensure a sterile insertion tube for each patient procedure.

Our strategy in the medical segment in FY 05 was comprised of three components: a) build on our improved sales distribution, b) continue to lower manufacturing costs and c) increase the number of new product offerings.

Since September 19, 2003, we have been distributing all of our products for the ENT market in the U.S.A. and Canada through Medtronic Xomed as part of the Medtronic Agreement. The initial term of the Medtronic Agreement is three years. Thereafter, the Medtronic Agreement is automatically renewed for successive one-year periods, unless terminated by either party upon advance written notice. Under the Medtronic Agreement, we have granted Medtronic Xomed exclusive distribution rights in the U.S.A. and Canada to market and sell our ENT and TNE EndoSheaths and endoscopes to ENT practitioners. Medtronic Xomed fulfilled certain minimum purchase requirements for the initial twelve-month period of the term. The Medtronic Agreement resulted in an increase in sales of our ENT EndoSheaths and ENT endoscopes due to the quantities of endoscopes and EndoSheaths purchased by Medtronic Xomed in the initial twelve-month period. In the second year ("Year 2") of the Medtronic

Agreement, Medtronic purchase fewer units of ENT endoscopes and ENT EndoSheaths than in the initial period, due to the build up of inventory that resulted from the purchases in the initial period. During Year 2, we and Medtronic Xomed began a rebate program, whereby we agreed to pay Medtronic a cash rebate for ENT EndoSheaths they sold to new users who committed to a large annual purchase. During FY 05, we recorded a reserve of approximately $45,000 for the rebate program. As of March 31, 2005, Medtronic Xomed had approximately 3.5 months of inventory of ENT EndoSheaths on hand. We expect in FY 06 that Medtronic Xomed will begin to purchase ENT EndoSheaths at an annualized rate of approximately 140,000 beginning in our second fiscal quarter ending September 30, 2005.

In addition, in December 2004, we signed an agreement (the "MGU Agreement") with Medtronic USA, Inc., the gastro-urology division of Medtronic, Inc. ("MGU") granting MGU exclusive rights to distribute our new cystoscope with Slide-On EndoSheath System to urologists in the U.S.A. and Canada. The term of the MGU Agreement is through March 31, 2006, renewable for successive one-year periods unless either party notifies the other party in writing at least 90 days prior to the end of any term that it does not want to renew. The total purchase commitment for cystoscopes and Slide-On EndoSheaths is $1,965,000, of which $353,500 was to be delivered in FY 05, and the remainder in FY 06.

We believe the marketing and sales capabilities of Medtronic Xomed and MGU have facilitated and will continue to facilitate the introduction of new products to the ENT and urology markets by allowing quicker market acceptance of these products than if we marketed them ourselves. As a result of these agreements, the success of our ENT and urology product lines is substantially dependent upon the success of the marketing and sales activities of Medtronic Xomed and MGU, over which we have limited control. We have retained our domestic network of independent sales representatives for the GI and pulmonary product lines. Also, we have retained our own international network of distributors for all our medical product lines.

In FY 04, we decided we could reduce manufacturing costs by sub-contracting the manufacture of our EndoSheaths to a company in Israel. We spent much of FY 05 executing a transition plan to that end. However, in May 2005, we realized that the transition was not going to be as successful as we had planned, due to a variety of issues surrounding quality, consistency of personnel and cost savings. As a result, we have decided to bring the manufacture of these products back to our Natick facility, and expect that to be completed during the second fiscal quarter of FY 06. Also during FY 06, we plan to implement reductions in the cost of materials and labor across our endoscope and EndoSheath product lines.

In FY 05, we received clearance from the FDA to market our TNE Bx endoscope with Slide-On EndoSheath system, and our cystoscope with Slide-On EndoSheath System. In addition, we released a line of peripheral products for ENT and urology physicians' offices. Our plans for product development in FY 06 include the new ENT-3000 portable endoscope with battery powered LED light source, design and cost improvements to our TNE D, TNE Bx and cystoscopes, a new low cost mass-production EndoSheath design and a new family of videoscopes. In May 2005, we received clearance from the FDA to market the ENT-3000 endoscope.

The industrial segment designs, manufactures and sells flexible endoscopes, termed borescopes, for industrial users, and manufactures and repairs flexible endoscopes for the medical segment. The

industrial segment users consist primarily of companies in the aircraft engine manufacturing and maintenance markets and the defense market.

The corporate segment consists of certain administrative and business development activities applicable to the company as a whole.

This discussion and analysis of our financial condition and results of operations is based upon our Consolidated Financial Statements, which have been prepared in accordance with accounting principles generally accepted in the United States. See the Notes to the Consolidated Financial Statements included elsewhere herein. Certain of our accounting policies require the application of judgment in selecting the appropriate assumptions for calculating financial estimates. By their nature these judgments are subject to an inherent degree of uncertainty. We periodically evaluate the judgments and estimates used for our critical accounting policies to ensure that such judgments and estimates are reasonable for our interim and year-end reporting requirements. These judgments and estimates are based upon our historical experience, current trends and information available from other sources, as appropriate. If different conditions result from those assumptions used in our judgment, the results could be materially different from our estimates. Our critical accounting policies include the following:

We recognize revenue in accordance with SEC Staff Accounting Bulletin No. 104, Revenue Recognition in Financial Statements (SAB 104). This pronouncement requires that five basic criteria must be met before revenue can be recognized: (1) persuasive evidence that an arrangement exists; (2) delivery has occurred or services rendered; (3) the fee is fixed and determinable; (4) collectibility is reasonably assured and (5) the fair value of undelivered elements, if any, exists. Determination of criterion (4) is based on management's judgment regarding the collectibility of invoices for products and services delivered to customers. Should changes in conditions cause management to determine this criteria is not met for certain future transactions, revenue recognized for any reporting period could be adversely affected. We recognize revenue when title passes to the customer, generally upon shipment of our products F.O.B. shipping point.

We sell our ENT products in the U.S.A. and Canada through Medtronic Xomed, according to the terms of the Medtronic Agreement. We sell our urology products in the U.S.A. and Canada through MGU, according to the terms of the MGU Agreement. Neither of these agreements provide for any terms related to product acceptance, warranty or contingencies, such as rights of return, that are different than the normal terms we grant to other customers. Both agreements provide for a discount for payment within 10 days of invoice for products shipped under the agreements.

During the fiscal year ended March 31, 2005, the Company and Medtronic Xomed modified the Medtronic Agreement to provide for a rebate to Medtronic Xomed for sales of ENT EndoSheaths to new customers who commit to large purchases. The rebate program is designed to run for one year to August 31, 2005. The Company accounts for this modification under Emerging Issues Task Force ("EITF") 01-9, Accounting for Consideration Given by a Vendor to a Customer (Including a Reseller of the Vendor's Products). During the fiscal year ended March 31, 2005, the Company provided for a reserve for rebates of approximately $45,000.

For FY 02 through FY 04, we accounted for certain non-qualified options granted to non-employees to purchase our common stock in accordance the EITF 00-19, Accounting for Derivative

Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock, and EITF 96-18, Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods and Services. In accordance with EITF 00-19, once vested these contracts were carried at fair value, with any changes in fair value recorded in the results of operations. Fair values for non-qualified options are derived from pricing models that consider current market and contractual prices for the underlying financial instruments or commodities, as well as time value and yield curve or volatility factors underlying the positions. Pricing models and their underlying assumptions impact the amount and timing of unrealized gains and losses recognized, and the use of different pricing models or assumptions could produce different financial results. The Company uses the Black-Scholes option pricing model to determine the fair market value of non-qualified options.

Effective March 31, 2004, we amended the non-qualified option agreements previously granted to non-employees. This amendment provides that we may settle our obligation to the holder by delivering unregistered shares to the holder. As a result of this amendment, we now account for these non-qualified options as equity instruments, and the fair market value of these options was transferred to the equity section of our balance sheet. Effective April 1, 2004 we account for options issued to non-employees in accordance with the provisions of EITF 96-18.

Under our income tax policy, we record the estimated future tax effects of temporary differences between the tax bases of assets and liabilities and amounts reported in the accompanying consolidated balance sheets, as well as operating loss and tax credit carryforwards. The evaluation of the recoverability of any tax assets recorded on the balance sheet is subject to significant judgment. We have provided valuation allowances for all our deferred tax assets to date.

Net sales in FY 05 were $10,325,973, an increase of $398,847, or 4%, compared to net sales in FY 04. Sales in the medical segment increased by $536,615, or 8%, to $7,237,221, while sales of the industrial segment decreased by $137,768, or 4% to $3,088,752. In the medical segment, sales by market in FY 05 and FY 04 were as follows ($000's):

Market	FY 05		FY 04		Increase (Decrease)			Percent
ENT	$	5,461	$	5,901	$	(440	)	(7	)%
Urology		761		—		761		100	%
GI		317		509		(192	)	(38	)%
Pulmonary		148		55		93		169	%
Other		550		236		314		133	%

Total medical	$	7,237	$	6,701	$	536		8	%

Sales to the ENT market include products for the domestic and international markets as follows:

ENT Market	FY 05		FY 04		Increase (Decrease)			Percent
Domestic	$	3,401	$	3,745	$	(344	)	(9	)%
International		2,060		2,156		(96	)	(4	)%

Total ENT	$	5,461	$	5,901	$	(440	)	(7	)%

Products	FY 05		FY 04		Increase (Decrease)			Percent
ENT Slide-On EndoSheaths	$	1,076	$	1,764	$	(688	)	(39	)%
ENT Endoscopes		785		862		(77	)	(9	)%
TNE D Slide-On EndoSheaths		25		113		(88	)	(78	)%
TNE D Endoscopes		566		795		(229	)	(29	)%
TNE Bx Slide-On EndoSheaths		36		—		36		100	%
TNE Bx Endoscopes		541		—		541		100	%
All other		372		211		161		76	%

Total Domestic ENT	$	3,401	$	3,745	$	(344	)	(9	)%

The primary reasons for the decrease in sales of products to the domestic ENT market was the build-up of inventory of Slide-On ENT EndoSheaths at Medtronic Xomed, our exclusive distributor of ENT products in the U.S. and Canada. This build-up was a result of a mismatch between the minimum quantities of the Slide-On ENT EndoSheaths that Medtronic Xomed was required to purchase under the Medtronic Agreement, and the slower than anticipated increase in sales. In addition, the market for TNE D endoscopes and EndoSheaths did not develop as quickly as we had hoped. Partially offsetting these decreases were sales of TNE Bx endoscopes and EndoSheaths, new products, and higher sales of other ENT products. Total sales to Medtronic Xomed in FY 05 were $3.58 million, an increase of approximately $0.65 million, or 22%, compared to $2.93 million in FY 04. Although Medtronic Xomed did not purchase the required number of ENT EndoSheaths to maintain their exclusivity under the Medtronic Agreement, we have not exercised our right to terminate their exclusivity, as we currently

believe they represent the best alternative for us to distribute our current line of ENT products and drive product acceptance of new ENT products in the domestic market.

During FY 05, we and Medtronic Xomed began a rebate program, whereby we offered Medtronic Xomed a cash rebate for the purchase by new customers of large amounts of ENT EndoSheaths in a one-year period. The program is designed to run until August 31, 2005. In FY 05, we recorded sales discounts of approximately $45,000 as a reserve for the rebate program. We do not expect significant change in that sales discount through August 2005, as Medtronic Xomed has indicated the price reductions under this program were not significant enough to entice customers who perform large numbers of ENT procedures to purchase EndoSheaths. The rebates ranged from $.02 to $1.17 per unit, depending upon the price received from the end-user by Medtronic Xomed.

In FY 06, we and Medtronic Xomed plan to introduce a more attractive pricing program, allowing the price for all new purchases to decline in steps. The first 150,000 units of ENT EndoSheaths purchased by Medtronic Xomed will be at the contract price; the next 100,000 will be at the contract price less $1.50 per unit; units over 250,000 will be at the contract price less $2.00 per unit. The purpose of this price schedule is to allow Medtronic Xomed to penetrate the market for large institutions and sell ENT EndoSheaths to them at prices those institutions find reasonable. In addition, we and Medtronic Xomed are having discussions to establish additional new programs that will increase the sales of our ENT and TNE products. We will most likely eliminate the rebate program when we finalize the step pricing schedule.

As a result of the Medtronic Agreement, the success of our ENT product lines are substantially dependent upon the success of the marketing and sales activities of Medtronic Xomed over which we have limited control.

Unit sales of ENT EndoSheaths to the domestic market were 150,400, a decrease of 60,345, or 29% compared to the 210,745 units sold in FY 04. The reduction in unit sales was directly related to the inventory build-up at Medtronic Xomed during the first year of the Medtronic Agreement. Unit sales of ENT endoscopes were 227, a decrease of 27, or 11%, compared to the unit sales of 254 in FY 04. Sales of ENT EndoSheaths and endoscopes include the sales of our ENT-2000 and ENT-1000. The ENT-1000 was released in FY 04.

During FY 05 we released the TNE Bx endoscope with Slide-On EndoSheath System. We recorded sales of these products to Medtronic Xomed in FY 05, but do not expect to generate significant sales in FY 06. This is due to the time required to validate the product with users, a project we and Medtronic Xomed are working on jointly.

Products	FY 05		FY 04		Increase (Decrease)			Percent
ENT Slide-On EndoSheaths	$	1,448	$	1,587	$	(139	)	(9	)%
ENT Endoscopes		443		496		(53	)	(11	)%
TNE D Slide-On EndoSheaths		7		2		5		250	%
TNE D Endoscopes		64		56		8		14	%
TNE Bx Slide-On EndoSheaths		5		—		5		100	%
TNE Bx Endoscopes		60		—		60		100	%
All other		33		15		18		120	%

Total International ENT	$	2,060	$	2,156	$	(96	)	(4	)%

Unit sales of ENT EndoSheaths to the international market were 231,754, a decrease of 41,437, or 15%, compared to unit sales of 273,191 in FY 04. The average selling price ("ASP") for ENT EndoSheaths was $6.25 in FY 05, an increase of 8% compared to $5.81 in FY 04. We announced this

price increase at the end of FY 04. We attribute some erosion of sales to the emergence in Europe of a competing manufacturer of sheaths. We believe this competitor is selling products with features that are within the claims of our patents. We are defending, and intend to continue to defend, our intellectual property rights vigorously. We believe our product quality, breadth of product offerings and financial resources are superior to the competitor's.

We sold 120 ENT endoscopes in FY 05, a decrease of 24 units, or 17%, compared to unit sales in FY 04. The ASP for ENT endoscopes was approximately 4% greater in FY 05 compared to FY 04, again due to price increases announced at the end of FY 04. The decrease in sales was due primarily to lower demand from Europe, due primarily to single payer systems overspending compared to their budgets, thus limiting expected purchases of endoscopes. Additionally, there are new high level disinfectants ("HLD") used to disinfect endoscopes in the market. While these HLDs are designed to be more compatible with the environment, their effect on materials used to manufacture endoscopes has, at times, been destructive. As a result, purchasers of endoscopes are requiring manufacturers to have statements of material compatibility with various types of HLDs. To address this challenge, we are including material compatibility studies in our FY 06 R&D plans.

During FY 05 we signed agreements with new distributors in Europe, Asia and the Middle East. Although sales to those distributors were not material in FY 05, we expect sales to all these new distributors and our current distributors will improve in FY 06 due to our marketing efforts, and to the continued release of the new products to them. During FY 05 we hired a new Vice President of Sales and Marketing for the medical segment. This allowed our Vice President of International Sales to concentrate on sales of ENT and other products in the international markets. In addition, we plan to continue to sign agreements with distributors in countries where we do not have a presence. As of May 31, 2005 we have 29 independent distributors, covering Europe, the Far East, Australia, South America and the Middle East.

In December 2004, we entered into the MGU Agreement with MGU. The MGU Agreement provides for MGU to be the exclusive distributor in the U.S. and Canada of our flexible cystoscope with Slide-On EndoSheath System and ancillary products to the urology market, including urogynecology. The MGU Agreement runs until March 31, 2006, the "Initial Term", and thereafter will automatically renew for successive one-year period, unless either party notifies the other party in writing, at least ninety days prior to the end of any term, of its intent not to renew.

During the Initial Term, MGU is required to purchase $1,965,000 of our flexible cystoscope with Slide-On EndoSheath Systems, of which $353,000 was to be purchased in FY 05, and $1,611,500 was to be purchased in FY 06. In the12-month periods following the Initial Term, the MGU Agreement requires us and MGU to negotiate minimum sales values. If MGU fails to purchase such minimums, or if we cannot agree on such minimums, we have the right and option to terminate MGU's exclusivity, or terminate the MGU Agreement. During FY 05, MGU purchased a total of approximately $359,000, comprised of $266,000 of cystoscopes and $93,000 of Slide-On EndoSheaths. In addition, MGU purchased approximately $112,000 of accessories.

As a result of the MGU Agreement, the success of our urology product lines is substantially dependent upon the success of the marketing and sales activities of MGU over which we have limited control.

In FY 05, we sold approximately $393,000 of cystoscopes and Slide-On EndoSheath Systems to our network of international distributors, primarily in Australia and Europe. In FY 06, we expect growth in this product line, as we add to the number of distributors selling it. We plan to sell through our current international distributor network, and also to expand this network to include distributors in countries where we do not presently sell our urology products.

Sales to the GI market declined by 38% in FY 05, compared to FY 04. We have a small group of users of these products, and we plan to continue to supply them with product in FY 06, but we expect sales of these products will continue to decline, compared to sales in FY 05. Sales to the pulmonary market increased. In December 2004 we announced we would be ceasing production of our EndoSheaths to the pulmonary market, and effective March 2005, increased the price of the EndoSheaths. This resulted in our receiving some orders from a small group of customers. We expect to fill these orders during the first half of FY 06, and then to eliminate it from our production plans until we can redesign it to better fit the needs of the market, and be less costly.

We believe the continued lack of reimbursement for the GI and pulmonary EndoSheaths by insurance companies to health-care providers, and that our endoscopes for these markets are fiberoptic, and not videoscopes, are the primary causes for the low sales of these products. In addition, we believe that colonoscopies, a more thorough examination of a person's colon, have grown faster than sigmoidoscopies in the market.

Sales in FY 05 of products in this segment decreased as demand for new borescopes declined from FY 04. The lower demand reflects the market's desire for video scopes, as opposed to fiberoptic scopes. We expect our sales of this product line will remain flat until we release our own line of video scopes.

Gross profit was $2,943,542, a decrease of $827,908, compared to FY 04. The gross profit of the medical segment decreased by approximately $948,300 to $1,848,400, and was 26% of sales, compared to 42% of sales in FY 04. Gross profit of the industrial segment increased by approximately $120,400 to $1,095,100 and was 35% of sales, compared to 30% of sales in FY 04.

The decrease in the gross profit of the medical segment was primarily due to the lower unit volume of ENT EndoSheaths, and negative gross profit for the initial production of cystoscope EndoSheaths. The lower gross profit from the initial production runs of EndoSheaths for the urology market is typical of new products. During FY 06 we plan to institute design and manufacturing changes to reduce the costs of these EndoSheaths to allow us to realize a positive gross profit from the manufacture of them. The lower gross profit from the ENT and cystoscope EndoSheaths was partially offset by higher gross profit derived from higher volumes of TNE D and TNE Bx endoscopes and cystoscopes.

During FY 04, we began the process of moving the manufacturing of our EndoSheaths to a sub-contractor in Israel, where we expected the unit costs of these products would decline by approximately 50%. The transfer of the manufacturing took longer than we had expected due to delays in the manufacturing of the equipment and difficulties inherent in the transfer of production techniques. We began receiving manufactured product from Israel at the end of our second fiscal quarter of FY 05. During the third and fourth fiscal quarters of FY 05, the Israeli sub-contractor manufactured EndoSheaths for the GI, ENT and urology markets. We also continued to manufacture some EndoSheaths for the ENT, pulmonary and urology markets in our Natick, MA facility. During the first fiscal quarter of FY 06, it became apparent that by utilizing the sub-contractor, we were not able to exert sufficient control over the manufacturing processes to have the confidence level we believe necessary for our product quality. In addition, we realized that the costs savings we had planned on by manufacturing our EndoSheaths in Israel were not going to be what we had expected. Thus, we have decided to move the production of our EndoSheaths back to our Natick, MA facility. We expect this transition will be completed during the second fiscal quarter of FY 06. We plan to ship all the

equipment currently at the subcontractor back to our facility in Natick. Depending upon demand for EndoSheaths and upon our ability to reconfigure some of the equipment to manufacture cystoscope or TNE EndoSheaths instead of ENT EndoSheaths, we may incur a charge for impairment in the second or third fiscal quarters of FY 06.

The higher gross profit in the industrial segment was due primarily to the higher volume of new product sold to customers, and to efficiencies attained by the increase in production and repair of endoscopes for the medical segment. In addition, the industrial segment was able to use inventory previously reserved for, totaling approximately $166,000, in the production and repair of endoscopes in FY 05, resulting in higher gross profit for these items. We expect the volume of sales to industrial customers of this segment will be flat in FY 06, but there can be no assurance that sales will not decline due to lower production of jet engines and reduced air travel. We plan to increase the quantity of endoscopes manufactured by the industrial segment for the medical segment by approximately 20% in FY 06. Although we expect this increase will result in increased absorption of overhead, we also expect we will incur an increase in the dollar amount of fixed overhead needed to manage this increased production.

Operating expenses increased by $1,151,926 in FY 05, compared to FY 04. Selling, general and administrative expenses ("SG&A") increased by $418,976, and research and development ("R&D") increased by $732,950. Operating expenses by segment in $000's were as follows.

Expense Category		FY 05		FY 04		Increase (Decrease)
SG&A
	Medical	$	1,924	$	1,709	$	215
	Industrial		801		711		90
	Corporate		1,172		1,058		114

Total SG&A		$	3,897	$	3,478	$	419

R&D
	Medical	$	1,380	$	641	$	739
	Corporate		41		47		(6	)

Total R&D		$	1,421	$	688	$	733

In the medical segment, the increase in SG&A expenses was due primarily to higher spending on sales and marketing of approximately $176,000 related to costs for product promotion, partially offset by lower spending on sales commissions of approximately $55,000, due to the elimination of our independent sales representative network for ENT products when we signed the Medtronic Agreement. In addition, we incurred higher costs for insurance of approximately $19,000, due primarily to higher premiums from increased sales; higher legal fees of approximately $19,000, related to filings for intellectual property; and higher charges of approximately $20,000 due primarily to changes to the charges to the reserve for uncollectible accounts for customers to whom we sold product directly prior to the Medtronic Agreement.

In the industrial segment, the increase in SG&A costs was due primarily to higher spending of approximately $18,500 for product promotion; higher spending of approximately $35,700 for rent of additional space at Orangeburg facility; higher spending of approximately $10,400 for shipping costs; and higher charges of approximately $23,300 for changes to charges to the reserve for uncollectible accounts.

In the corporate segment, SG&A costs increased by approximately $114,000 due primarily to severance costs for separation from service of a corporate officer.

R&D expenses increased in the medical segment by approximately $739,000, while declining by approximately $6,000 in the corporate segment. In the medical segment costs for personnel to work on projects increased by approximately $500,000. The remainder of the increase was due primarily to costs related to the development of new products: TNE Bx scope and Slide-On EndoSheath System, cystoscope with Slide-On EndoSheath System, the line of peripheral products for image capture and archiving. In the corporate segment, we reduced our efforts in Israel for CMOS patent applications, and do not expect to incur costs for these patent applications in FY 06. We expect our R&D expense will be greater in FY 06 than in FY 05 due to development efforts regarding new technologies that will enhance the competitive position of our endoscopes, and to efforts that will allow us to achieve a new EndoSheath design that is very low cost and manufactured using a fully automated production process. Our goal remains to achieve products where we believe our EndoSheath technology can increase physicians' practice efficiency, and provide for patient safety.

The reduction in expense for stock-based compensation was due primarily to the change in accounting that no longer required the periodic marking to market of our non-qualified options issued to non-employees. This accounting had resulted in a charge in FY 04 of $3,398,036 for an increase in the fair market value of non-qualified stock options granted to non-employees, of which approximately $2.9 million was incurred in our fourth fiscal quarter. As of March 31, 2004, we amended the contracts to allow us to issue unregistered securities to option holders upon their exercise. This change resulted in a reclassification of these non-qualified stock options from liability instruments to equity instruments. Consequently, we accounted for these and new options granted to non-employees in accordance with EITF 96-18 in FY 05.

Interest income increased, due primarily to higher cash balances in February and March 2005 subsequent to the issuance of new equity. Other income decreased slightly due to higher royalties received on a patent licensed to a company in the urology market, offset by higher royalties paid for a patent licensed for the production of a component used in our pulmonary and urology EndoSheaths.

Net sales in FY 04 were $9,927,126, an increase of $3,497,484, or 54%, compared to net sales in FY 03. Sales in the medical segment increased by $2,925,540, or 77%, to $6,700,606, while sales of the industrial segment increased by $571,944, or 22% to $3,226,520. In the medical segment, sales by market in FY 04 and FY 03 were as follows ($000's):

Market	FY 04		FY 03		Increase (Decrease)			Percent
ENT	$	5,901	$	3,070	$	2,831		92	%
GI		509		463		46		10	%
Pulmonary		55		83		(28	)	(34	)%
Other		236		159		77		48	%

Total medical	$	6,701	$	3,775	$	2,926		77	%

Sales to the ENT market include products for the domestic and international markets as follows:

ENT Market	FY 04		FY 03		Increase (Decrease)		Percent
Domestic	$	3,745	$	1,748	$	1,997	114	%
International		2,156		1,322		834	63	%

Total ENT	$	5,901	$	3,070	$	2,831	92	%

Products	FY 04		FY 03		Increase (Decrease)		Percent
ENT Slide-On EndoSheaths	$	1,764	$	1,431	$	333	23	%
ENT Endoscopes		862		317		545	172	%
TNE D Slide-On EndoSheaths		113		—		113	100	%
TNE D Endoscopes		795		—		795	100	%
All other		211		—		211	100	%

Total Domestic ENT	$	3,745	$	1,748	$	1,997	114	%

The primary reasons for the increase in sales of products to the domestic ENT market were the changing of our distribution method from independent sales representatives to exclusive distribution in the U.S. and Canada with Medtronic Xomed, and the release of several new products. As of March 31, 2004, Medtronic Xomed purchased more than the quantity of ENT endoscopes and EndoSheaths that they contracted to purchase in the first year of the Medtronic Agreement. In addition, Medtronic Xomed purchased our flexible TNE D scope with Slide-On EndoSheath System, as well as a variety of accessories, for resale in the ENT market. Total sales to Medtronic Xomed in FY 04 were approximately $2.9 million.

Unit sales of ENT EndoSheaths to the domestic market were 210,745, an increase of 58%, compared to unit sales in FY 03. Unit sales of ENT endoscopes were 254, an increase of 175, or 222%, compared to unit sales in FY 03. Sales of ENT EndoSheaths and endoscopes include the sales of our ENT-2000 and ENT-1000. The ENT-1000 was released in FY 04. The average unit sales price ("ASP") for ENT EndoSheaths and ENT endoscopes declined in FY 04, compared to FY 03, due to the Medtronic Agreement. However, the higher volume more than offset those price decreases.

During FY 04, we released the Slide-On ENT Sensory EndoSheath, the flexible TNE D scope with Slide-On EndoSheath System and our ENT-1000 endoscope with Slide-On EndoSheath System. We recorded sales of all these products, with the TNE D scope with Slide-On EndoSheath System being the most prominent.

Products	FY 04		FY 03		Increase (Decrease)		Percent
ENT Slide-On EndoSheaths	$	1,587	$	1,064	$	523	49	%
ENT Endoscopes		496		258		238	92	%
TNE D Slide-On EndoSheaths		2		—		2	100	%
TNE D Endoscopes		56		—		56	100	%
All other		15		—		15	100	%

Total International ENT	$	2,156	$	1,322	$	834	63	%

Unit sales of ENT EndoSheaths to the international market were 273,191, an increase of 50%, compared to unit sales in FY 03. We sold 144 ENT endoscopes in FY 04, an increase of 89%, compared to unit sales in FY 03. The ASP for ENT EndoSheaths and ENT endoscopes were approximately the same in FY 04, compared to FY 03. The increase in sales was due primarily to higher demand from Europe, where health care providers consider the use of the ENT EndoSheaths to be a cost-effective alternative to the time-consuming process of having to disinfect endoscopes after each use. Also in FY 04, the value of the U.S. Dollar in relation to the Euro resulted in a favorable competitive advantage to our ENT endoscope, compared to the cost of endoscopes manufactured in other countries in Europe. In FY 05 we plan to increase the prices of the ENT endoscope and ENT EndoSheath by 5% and 8%, respectively. Our internal analysis of the effect of this price increase on units sold in FY 04 indicated approximately 13% of the increase in the sales of EndoSheath units likely were caused by advance purchases by our international distributors.

During FY 04, we signed agreements with three new distributors in Europe and the Middle East. Sales to those distributors were not material in FY 04. As of May 31, 2004 we had 23 independent distributors, covering Europe, the Far East, Australia, South America and the Middle East.

Sales of endoscopes and EndoSheaths to the GI market continue to show little growth. Sales of endoscopes and EndoSheaths to the pulmonary market decreased. We have a small group of users of these products, and we continued to supply them with product in FY 05. We believe the continued lack of reimbursement for the GI and pulmonary EndoSheath by insurance companies to health care providers is the primary cause for this lower demand. We increased the price of these EndoSheaths in November 2002 to help us recover our costs to manufacture them.

Sales in FY 04 of products in this segment increased as demand for new borescopes rebounded from prior years.

Gross profit was $3,771,450, an increase of $2,104,220, compared to FY 03. The gross profit of the medical segment increased by approximately $1,775,000 to $2,796,000, and was 42% of sales, compared to 27% of sales in FY 03. Gross profit of the industrial segment increased by approximately $329,000 to $975,000 and was 30% of sales, compared to 24% of sales in FY 03.

The increase in the gross profit of the medical segment was primarily due to the higher unit volume of ENT EndoSheaths and endoscopes for the ENT market, including the new TNE D scope. In FY 04 we experienced the full effect of the new machinery in Natick, MA used to manufacture ENT EndoSheaths that helped to reduce our standard unit costs by approximately 43%. In addition, we controlled our spending for fixed overhead expenses, increasing our efficiency and allowing us to realize a large portion of the gross profit generated by the higher unit volume.

During FY 04, we began the process of moving the manufacturing of our GI and pulmonary EndoSheaths to a sub-contractor in Israel. We advanced $267,500 to the subcontractor for the purchase and installation of machinery to produce ENT EndoSheaths. The transfer of the manufacturing of the GI and pulmonary products and the installation of the line of ENT manufacturing equipment took longer than we had expected due to delays in the manufacturing of the equipment and difficulties inherent in the transfer of production techniques.

Operating expenses increased by $625,784 in FY 04, compared to FY 03. SG&A increased by $363,367, and R&D increased by $262,417. Operating expenses by segment in $000's were as follows.

Expense Category		FY 04		FY 03		Increase (Decrease)
SG&A
	Medical	$	1,709	$	1,664	$	45
	Industrial		711		811		(100	)
	Corporate		1,058		640		418

Total SG&A		$	3,478	$	3,115	$	363

R&D
	Medical	$	641	$	352	$	289
	Corporate		47		74		(27	)

Total R&D		$	688	$	426	$	262

In the medical segment, the increase in SG&A expenses was due primarily to higher spending on legal fees related to intellectual property of approximately $75,000, and higher spending for marketing consulting of approximately $83,000. These were partially offset by lower spending for sales commissions of approximately $114,000, due to the elimination of our independent sales representative network for ENT products when we signed the Medtronic Agreement. In the industrial segment, the decline in SG&A costs was due primarily to lower personnel costs of approximately $45,000, lower charges for depreciation of approximately $31,000 and lower spending for travel and entertainment of approximately $22,000. In the corporate segment, the increase in SG&A costs was due primarily to higher personnel costs of approximately $173,000, due to a full year of salary for our CEO, higher charges for professional fees of approximately $203,000, due to fees related to the Medtronic Agreement and the 3BY Agreements and severance costs of $35,000, due to the separation from service of a corporate officer.

The increase in R&D in the medical segment costs was primarily for personnel to work on projects increased by approximately $150,000. The remainder of the increase was due primarily to costs related

to the development of new products. In the corporate segment, we reduced our efforts in Israel for the CMOS patent applications.

We recorded a charge of $3,398,036 for an increase in the fair market value of non-qualified stock options granted to non-employees, of which approximately $2.9 million was incurred in our fourth fiscal quarter. See footnote 1(m) in the attached financial statements. We used the Black-Scholes option pricing model to value these options, a primary component of which is the fair market value of the underlying common stock at the date of valuation. Our stock price increased from $1.72 per share at December 31, 2003 to $3.69 at March 31, 2004, resulting in the largest component of the charge. As of March 31, 2004, we amended the contracts to allow us to issue unregistered securities to option holders upon their exercise. This change resulted in a reclassification of these non-qualified stock options from liability instruments to equity instruments. After this change we accounted for these options in accordance with EITF 96-18.

Interest income declined, due primarily to lower interest rates during FY 04. Other income increased slightly due to higher royalties on a patent licensed to a company in the urology market.

Our net loss was $3,748,203, or $.12 per share. This compares to a loss of $1,707,095, or $.06 per share in FY 03. The number of shares increased due to the sale of new shares in April 2003 and option exercises by employees and non-employees during FY 04.

In FY 05, the amount of cash used in our operations was approximately $2,309,000, compared to a usage of approximately $741,000 in FY 04. This increased usage was due primarily to lower gross profits and higher spending for SG&A and R&D. We also incurred an increase in inventory, primarily related to raw materials and finished goods for TNE D, TNE Bx, cystoscope and their companion EndoSheaths. We expect our working capital needs will increase in FY 06, especially for accounts receivable due to higher sales, and to inventory due to manufacturing a broader range of product offerings and a desire to build safety stock for some key inventory components.

Cash used in investing activities was approximately $681,000, comprised of spending for the purchase of property and equipment to support our increased production, leasehold improvements in Natick and Orangeburg and the purchase and installation of new computers. In addition, we converted the advance to 3BY Ltd of $267,500 to fixed assets in a non-cash transaction by taking title to the equipment effective October 1, 2004. We expect we will spend approximately $860,000 for new property, plant and equipment in FY 06, primarily for production equipment related to the manufacture of new products, and for equipment related to automating current products.

Cash generated from financing activities totaled approximately $10,144,000. The primary source of this cash was the sale of 3.7 million new shares in February 2005 that generated approximately $9.44 million, net, and the exercise of options to purchase common stock by employees and non-employees during the fiscal year that generated approximately $0.75 million. There are approximately 2.8 million vested options to purchase Common Stock outstanding at March 31, 2005, split between employees (55%) and non-employees (45%). These options have a weighted average exercise price of $1.35 per share. It is possible some of these options will be exercised in FY 06.

The primary composition of customers in the medical segment includes Medtronic Xomed, MGU and international distributors. We have good relations with all these customers and expect our collection experience will remain approximately the same in FY 06 as in FY 05. Our days sales outstanding ("DSO"), a calculation of the number of calendar days that accounts receivable remain unpaid, at March 31, 2005 for the medical segment was 44, an increase of 11 days, compared to

March 31, 2004. This increase was due primarily to a change in the composition of our accounts receivable. We sold less to Medtronic Xomed, especially in the last fiscal quarter of FY 05, compared to FY 04. Medtronic Xomed usually pays their invoices within 14 days of shipment. Other customers, notable our international distributors pay in 30-60 days from date of invoice. The composition of customers in the industrial segment includes large and small industrial companies, and aircraft maintenance companies. The DSO for that group of customers was 69 at March 31, 2005, compared to 47 at March 31, 2004. The increase is due to relatively large sales to a few customers who are relatively slower payers. We monitor our customer accounts formally on a monthly basis, and more often as necessary. During FY 05, the change in the composition of our accounts receivable and our experience of slower collections from them resulted in a lower confidence level in the balance of accounts receivable, resulting in an increase in the allowance for doubtful accounts of approximately $17,000, net. We will continue to monitor our receivables and will adjust the allowance for doubtful accounts accordingly.

At March 31, 2005, our principal sources of liquidity included $9.9 million in cash and cash equivalents. In July 2004, we renewed our bank agreement, which is subject to renewal again in July 2005. This bank agreement includes a revolving line of credit under which we may borrow up to $1,000,000, net of up to $250,000 of any outstanding letters of credit and banker's acceptances. Borrowings under these loan arrangements must be fully cash collateralized. The agreement also stipulates that when we achieve positive cash flow, as defined in the agreement, we will be eligible to negotiate changes to these loan arrangements that may include changing the borrowing base for revolving loans, and the release of the pledged cash collateral. Any borrowing under this demand line would bear interest at the prime rate, which was 5.75% on March 31, 2005.

We have incurred losses since our inception, and we expect to incur losses in FY 06. We have funded the losses principally with the proceeds from public and private equity financings. We expect to use approximately $3.7 million of cash in FY 06, approximately 70% in the first half of the fiscal year, as we continue to spend on the development of new products, and on sales and marketing costs to establish new distribution channels. Our plans are to increase sales by increasing our market penetration of products developed in FY 05, and also from new products developed in FY 06. There can be no assurance that our strategy will result in higher sales during FY 06, and we may seek equity capital during FY 06. However, there can be no assurance that capital will be available on terms acceptable to us, if at all.

The following chart summarizes our contractual obligations as of March 31, 2005.

	Payment Due by Period
Contractual Obligations	Total		Less than 1 year		Between 1-3 years		Between 3-5 years		More than 5 years
Operating leases	$	1,353,090	$	400,639	$	520,192	$	364,551	$	67,708
Long term debt		44,932		22,466		22,466		0		0
Purchase commitments		4,167,000		4,167,000		0		0		0

Total	$	5,565,022	$	4,590,105	$	542,658	$	364,551	$	67,708

We have no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Factors that may affect our future operating results include, without limitation, the following:

We have incurred substantial losses since our inception, and there can be no assurance that we will achieve a profitable level of operations in the future. We anticipate a negative cash flow during FY 06, due primarily to spending for R&D, operations and capital expenditures. We had cash and marketable securities totaling $9.9 million as of March 31, 2005. Although we do not anticipate the need for additional financing in FY 06, management may seek new financing, if terms are favorable. However, there can be no assurance that such financing will be available on terms acceptable to us, if at all.

There can be no assurance that third-party reimbursement will continue to be available for procedures performed with our products. In addition, reimbursement standards and rates may change. We believe that the failure of users of our GI and pulmonary products to obtain adequate reimbursement from third-party payors has had a materially adverse effect on our sales.

Our products and manufacturing practices are subject to regulation by the FDA and by other state and foreign regulatory agencies. The process of obtaining required regulatory clearances can be lengthy and expensive, and compliance with the FDA's QSR can be burdensome. Moreover, there can be no assurance that the required regulatory clearances will be obtained, and those obtained may include significant limitations on the uses of the product in question. In addition, changes in existing regulations or the adoption of new regulations could make regulatory compliance by us more difficult in the future. The failure to obtain the required regulatory clearances or to comply with applicable regulations may result in fines, delays, suspensions of clearances, seizures, recalls of products, operating restrictions or criminal prosecutions, and could have a material adverse effect on our operations.

Certain critical components of our products, such as image bundles, are currently being purchased solely from Pentax, a competitor of ours. These components are being purchased pursuant to a supply agreement, which expires in March 2005, subject to earlier termination by mutual consent or upon breach or bankruptcy, and which may be extended with the consent of both parties. We believe that while substitute components, which are currently produced by sources other than Pentax, would be available, such substitute components may be more expensive and of a lower quality and may require a redesign of our endoscope and additional regulatory clearances. Moreover, such substitute components may not be immediately available in quantities needed by us. Our inability to obtain a sufficient quantity of such critical components on favorable terms could materially adversely affect our business. In addition, our industrial borescopes are assembled using components and subassemblies purchased from independent vendors. While most components and subassemblies are currently available from more than one supplier, certain critical components are currently purchased only from Pentax and Machida Endoscope Company, Ltd. The failure of us to obtain a sufficient quantity of such components on favorable terms could materially adversely affect our business.

Our ability to compete in our markets is affected by our product development and innovation capabilities, our ability to obtain required regulatory clearances, our ability to protect the proprietary technology included in our products, our manufacturing and marketing skills and our ability to attract and retain skilled employees. The flexible endoscopes and related products currently sold and under development by us face competition primarily from medical products companies such as Olympus and Pentax. In addition, any company that is able to significantly redesign conventional flexible endoscopes to simplify the cleaning process, or significantly improve the current methods of cleaning flexible endoscopes, would provide competition for our products. The principal competitors for our industrial products are Olympus and Welch Allyn. Many of our competitors and potential competitors have greater financial resources, research and development personnel, and manufacturing and marketing capabilities than we have. In addition, it is possible that other large health care companies may enter the flexible endoscope market in the future.

Our success depends in part on our ability to maintain patent protection for our products, to preserve our trade secrets and to operate without infringing the proprietary rights of third parties. There can be no assurance that our pending patent applications will result in patents being issued or that our competitors will not circumvent, or challenge the validity of, any patents issued to us. There can be no assurance that measures taken by us to protect our proprietary information will prevent the unauthorized disclosure or use of this information, or that others will not be able to independently develop such information. In addition, in the event that another party infringes our patent rights or other proprietary rights, the enforcement of such rights is at our option and can be a lengthy and costly process, with no guarantee of success. Moreover, there can be no assurance that claims alleging infringement by us of other's proprietary rights will not be brought against us in the future or that any such claims will not be successful.

The nature of our products exposes us to significant product liability risks. We maintain product liability insurance with coverage limits of $2,000,000 per year. We believe that this level of coverage is adequate, given our past sales levels, our anticipated sales levels for FY 06 and our claims experience. We will reevaluate the adequacy of this coverage when and if our sales substantially increase. No product liability claims have been brought against us to date. However, there can be no assurance that product liability insurance will continue to be available to us on acceptable terms, or that product liability claims in excess of our insurance coverage, if any, will not be successfully asserted against us in the future.

In December 2004, the FASB issued SFAS No. 123 (revised 2004), Share-Based Payment (SFAS 123R). SFAS 123R is a revision of SFAS No. 123, Accounting for Stock-Based Compensation and supersedes APB No. 25, Accounting for Stock Issued to Employees, and its related implementation guidance. SFAS 123R requires all share-based payments to employees, including grants of employee stock options, to be recognized in the financial statements based on their fair values beginning with the first interim or annual period after June 15, 2005, with early adoption encouraged. The proforma disclosures previously permitted under SFAS 123 no longer will be an alternative to financial statement recognition. The Company is required to adopt SFAS 123R in the first quarter of fiscal 2007, beginning April 1, 2006. Under SFAS 123R, the Company must determine the appropriate fair value model to be used for valuing share-based payments, the amortization method for compensation costs and the transition method to be used at date of adoption. The transition methods include prospective and retrospective adoption options. Under the retroactive option, prior periods may be restated either as of the beginning of the year of adoption or for all periods presented. The prospective method requires that compensation expense be recorded for all unvested stock options and restricted stock at the beginning of the first quarter of adoption of SFAS 123R, while the retroactive method would record compensation expense for all unvested stock options and restricted stock beginning with the first period restated. The Company is evaluating the requirements of SFAS 123R and expects that the adoption of

SFAS 123R may have a material impact on its consolidated results of operations and earnings per share. The Company has not yet determined the method of adoption or the effect of adopting SFAS 123R, and it has not determined whether the adoption will result in amounts that are similar to the current pro forma disclosures under SFAS 123.

We, in the normal course of business, are subject to the risks associated with fluctuations in interest rates and changes in foreign currency exchange rates.

We attempt to limit our exposure to interest rate and credit risk by placing our investments with high-quality financial institutions and we have established investment guidelines relative to diversification and maturities designed to maintain safety and liquidity. We have not used derivative financial instruments in our investment portfolio.

Investments in both fixed rate and floating rate interest earning instruments carry a degree of interest rate risk. Fixed rate securities may have their fair market value adversely impacted due to a rise in interest rates, while floating rate securities may produce less income than expected if interest rates decline. Due in part to these factors, our future investment income may fall short of expectations due to changes in interest rates or we may suffer losses in principal if forced to sell securities which have seen a decline in market value due to changes in interest rates.

We face exposure to adverse movements in the value of the Japanese yen due to purchases of raw materials from Japanese suppliers. This exposure may change over time, and could have a materially adverse effect on our financial results. We may attempt to limit this exposure by purchasing forward contracts, as required. Most of our liabilities are settled within 90 days of receipt of materials. At March 31, 2005, our liabilities relating to Japanese yen were approximately $44,000.

Financial statements and unaudited supplementary data are contained in Appendix A to this annual report on Form 10-K.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Our Chief Executive Officer and Chief Financial Officer have reviewed and evaluated the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 240.13a-15e) and 15d-15(e) as of March 31, 2005, the end of the period covered by this annual report on Form 10-K. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that our current disclosure controls and procedures are effective.

There were no changes in our internal controls over financial reporting that occurred during the fiscal quarter ended March 31, 2005 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

The information required by this Item appears under the headings "Proposal 1: Election of Directors" and "Section 16(a) Beneficial Ownership Reporting Compliance" in our Proxy Statement for our 2005 Annual Meeting of Stockholders (the "2005 Proxy Statement"), which sections are incorporated herein by reference, and in Part I hereof under the caption "Executive Officers of the Company".

The information regarding our code of ethics and the audit committee and audit committee financial experts is contained under the captions "Code of Ethics" and "Report of the Audit Committee of the Board of Directors", respectively, in our 2005 Proxy Statement.

The information required by this Item appears under the headings "Proposal 1: Election of Directors—Director Compensation", "—Executive Compensation", "—Agreements with Named Executive Officers", and "—Compensation Committee Report on Executive Compensation" in the 2005 Proxy Statement, which sections are incorporated herein by reference.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The information required by this Item appears under the heading "Stock Ownership of Certain Beneficial Owners and Managers" in the 2005 Proxy Statement, which section is incorporated herein by reference, and in Part II hereof under the caption "Securities Authorized for Issuance Under Equity Compensation Plans".

The information required by this Item appears under the heading "Certain Relationships and Related Transactions" in the 2005 Proxy Statement, which section is incorporated herein by reference, and in Part II hereof under the caption "Market for Registrant's Common Stock and Related Stockholder Matters".

The information required in this Item appears under the heading "Fees and Services" in the 2005 Proxy Statement which section is incorporated herein by reference.

Pursuant to the requirements of Sections 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the date indicated.

Signature	Title	Date

/s/ RON HADANI Ron Hadani	President and CEO (Principal Executive Officer), Director	June 29, 2005
/s/ JAMES A. TRACY James A. Tracy	Vice President Finance, Chief Financial and Accounting Officer (Principal Financial and Accounting Officer)	June 29, 2005
/s/ KATSUMI ONEDA Katsumi Oneda	Chairman of the Board of Directors	June 24, 2005
/s/ LEWIS C. PELL Lewis C. Pell	Vice Chairman of the Board of Directors	June 24, 2005
/s/ KENNETH ANSTEY Kenneth Anstey	Director	June 16, 2005
William F. Doyle	Director	June , 2005
/s/ JOHN J. WALLACE John J. Wallace	Director	June 16, 2005

CONSOLIDATED FINANCIAL STATEMENTS
as of March 31, 2004 and 2005
Together with Report of Independent Registered
Public Accounting Firm

		Page
Report of Independent Registered Public Accounting Firm		F-1
Consolidated Balance Sheets		F-2
Consolidated Statements of Operations		F-3
Consolidated Statements of Stockholders' Equity		F-4
Consolidated Statements of Cash Flows		F-5
Notes to Consolidated Financial Statements		F-6

To the Shareholders and Board of Directors of Vision-Sciences, Inc. and Subsidiaries:

We have audited the accompanying consolidated balance sheets of Vision-Sciences, Inc. and subsidiaries as of March 31, 2004 and 2005 and the related consolidated statements of operations, stockholders' equity and comprehensive loss and cash flows for each of the three years in the period ended March 31, 2005. These financial statements are the responsibility of Vision-Sciences, Inc.'s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Vision-Sciences, Inc. and subsidiaries as of March 31, 2004 and 2005 and the consolidated results of their operations and their cash flows for each of the three years in the period ended March 31, 2005, in conformity with generally accepted accounting principles in the United States of America.

Vision-Sciences, Inc. and Subsidiaries

Consolidated Balance Sheets—March 31, 2004 and 2005

The accompanying notes are an integral part of these consolidated financial statements.

Vision-Sciences, Inc. and Subsidiaries

Consolidated Statements of Operations

for the Fiscal Years Ended March 31, 2003, 2004 and 2005

The accompanying notes are an integral part of these consolidated financial statements.

Vision-Sciences, Inc. and subsidiaries

Consolidated Statements of Stockholders' Equity and Comprehensive Loss

for the Fiscal Years Ended March 31, 2003, 2004 and 2005

The accompanying notes are an integral part of these consolidated financial statements.

Vision-Sciences, Inc. and Subsidiaries

Consolidated Statements of Cash Flows

for the Fiscal Years Ended March 31, 2003, 2004 and 2005

The accompanying notes are an integral part of these consolidated financial statements.

VISION-SCIENCES, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

MARCH 31, 2005

The consolidated financial statements include the accounts of Vision-Sciences, Inc. (the "Company"), a Delaware corporation, and its wholly-owned subsidiaries. The Company's subsidiaries are as follows: OpieLab, Inc., a Washington corporation; Machida Incorporated, a Delaware corporation; and Vision Sciences Ltd., an Israeli corporation. Vision Sciences Ltd. has been inactive since the fiscal year ended March 31, 2002.

The Company was organized in 1987 to manufacture and assemble optical products. The Company's products and accessories are used within two industry segments, medical and industrial. The medical segment designs, manufactures and markets proprietary single-use sheaths that slide onto the insertion tube of flexible endoscopes used by health-care providers. The sheaths allow quick, efficient product turnover for health-care providers while ensuring a sterile insertion tube for each patient. The medical segment also designs and markets flexible endoscopes for use by physicians in the Ear-Nose-Throat ("ENT"), urology, pulmonary and gastrointestinal ("GI") markets. The industrial segment designs, manufactures and markets borescopes for the industrial market, and manufactures and repairs endoscopes for the medical segment. Endoscopes and borescopes provide minimally invasive access to areas not readily visible to the human eye. Segment information is presented in Note 8.

The Company expects to derive a substantial portion of its future revenues from its various endoscope and EndoSheath Sytems. The Company has invested substantial funds developing these products. The Company has incurred losses for the fiscal years ended March 31, 2003, 2004 and 2005, and expects to incur a loss for the fiscal year ending March 31, 2006. In February 2005, the Company sold 3,672,315 shares of Common Stock, raising gross proceeds of approximately $10,093,000. As a result, management believes the Company will not require additional financial support for fiscal year 2006. However, management may seek additional equity capital during fiscal 2006, and the Company may require more financing to fund operations in the future. The Company is also subject to risks, including, but not limited to, the successful marketing of its products, United States Food and Drug Administration ("FDA") clearance and regulation, and dependence on key personnel.

The accompanying consolidated financial statements reflect the application of certain accounting policies as described below and elsewhere in the notes to the consolidated financial statements. The preparation of the accompanying consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results in the future could differ from those estimates.

The accompanying consolidated financial statements reflect the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

The Company calculates earnings per share according to Statement of Financial Accounting Standards (SFAS) No. 128, Earnings per Share. Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding. For the years ended March 31, 2003, 2004 and 2005, diluted net loss per common share is the same as basic net loss per common share as the inclusion of other shares of stock issuable pursuant to stock options, totaling 4,051,082, 4,680,664 and 4,414,548 respectively, would be antidilutive.

The Company provides for depreciation and amortization using the straight-line method in amounts that allocate the cost of the assets over their estimated useful lives, as follows:

Asset Classification		Estimated Useful Life
Machinery and equipment		3-5 years
Furniture and fixtures		5 years

Leasehold improvements are amortized over the shorter of their estimated useful lives or the lives of the leases.

The following must occur before the Company recognizes revenue: (1) persuasive evidence of an arrangement exists, (2) delivery has occurred or services have been rendered, (3) the price is fixed or determinable, (4) collectibility is reasonably assured and (5) the fair value of undelivered elements, if any, exists. To date, the Company has not entered into any multiple element arrangements. The Company recognizes revenue when title passes to the customer, generally upon shipment of products F.O.B. shipping point. Since September 2003, the Company's medical segment has distributed all of its products for the ENT market in the U.S.A. and Canada through Medtronic Xomed as part of the Medtronic Agreement. The initial term of the Medtronic Agreement was three years, renewable thereafter annually, unless terminated by either party.

During the fiscal year ended March 31, 2005, the Company and Medtronic Xomed modified the Medtronic Agreement to provide for a rebate to Medtronic Xomed for sales of ENT EndoSheaths to new customers who commit to large purchases. The rebate program is designed to run for one year to September 30, 2005. The Company accounts for this modification under Emerging Issues Task Force ("EITF") 01-9, Accounting for Consideration Given by a Vendor to a Customer (Including a Reseller of the Vendor's Products). During the fiscal year ended March 31, 2005, the Company provided for rebates of approximately $45,000.

In December 2004, we signed an agreement (the "MGU Agreement") with Medtronic USA, Inc., the gastro-urology division of Medtronic, Inc. ("MGU") granting MGU exclusive rights to distribute our new cytoscope with Slide-On EndoSheath System to urologists in the U.S.A. and Canada. The term of the MGU Agreement is through March 31, 2006, renewable for successive one-year periods unless either party notifies the other party in writing at least 90 days prior to the end of any term that it does not want to renew.

Neither the Medtronic Agreement nor the Medtronic USA Agreement provide for any contingencies, nor provide any terms related to product acceptance or warranty that are different from the normal terms provided by the Company to its other customers.

The Company's medical segment distributes its products for the pulmonary and GI markets through a network of independent domestic sales representatives. The Company's medical segment distributes all its products outside the USA and Canada through a network of independent international distributors.

The Company's industrial segment distributes all its products using direct sales personnel and a network of independent sales representatives.

Inventories are stated at the lower of cost or market using the first-in, first-out (FIFO) method. The components of inventories are as follows:

	March 31,
	2004		2005
Raw materials	$	726,221	$	1,166,946
Work-in-process		297,220		253,449
Finished goods		329,275		456,429

	$	1,352,716	$	1,876,824

Raw materials include components purchased from independent suppliers. Most purchased components are available from multiple sources. With the exception of a supply agreement with Pentax, the Company does not have long-term agreements with suppliers. The agreement with Pentax expired in March 2005, and the Company expects to renew this agreement in the fiscal year ending March 31, 2006. If the agreement with Pentax is not renewed on favorable terms, the Company would have to purchase the required components from other suppliers, a process that might require re-design of its products. Work-in-process and finished goods inventories consist of materials, labor and manufacturing overhead. The Company purchased approximately $1,477,000 and $1,867,000 of products under the supply agreement with Pentax in the years ended March 31, 2004 and 2005, respectively.

Other assets consist of deposits and $96,790 of patent costs. Patent costs are amortized on a straight-line basis over 17 years.

In accordance with SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets, the Company reviews the carrying values of its long-lived assets for possible impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. The Company believes that the carrying value of these assets is fully realizable at March 31, 2005.

The Company charges foreign currency exchange gains or losses in connection with its purchases of products from vendors in Japan to operations in accordance with SFAS No. 52, Foreign Currency Translation. For each of the three years in the period ended March 31, 2005, these amounts were not material.

The Company classifies investments with original maturities of ninety days or less, consisting of a money market account at a bank, as cash equivalents. Cash equivalents are stated at amortized cost, which approximates market value.

SFAS No. 105, Disclosure of Information about Financial Instruments with Off-Balance-Sheet Risk and Financial Instruments with Concentration of Credit Risk, requires disclosure of any significant off-balance-sheet and credit risk concentrations. Financial instruments that potentially subject the Company to concentration of credit risk are principally cash, marketable securities and accounts receivable. The Company places its cash in federally insured institutions and invests in highly-rated investment vehicles. Concentration of credit risk with respect to accounts receivable relates to certain domestic and international customers to whom the Company makes substantial sales (see Note 8). To reduce risk, the Company routinely assesses the financial strength of its customers and, when appropriate, obtains letters of credit or advance payments for its international sales; as a consequence, the Company believes that its accounts receivable credit risk exposure is limited. The Company had three customers who accounted for 17%, 15% and 11%, respectively, of the total accounts receivable balance at March 31, 2005. The Company had one customer who individually accounted for 39% of the total accounts receivable balance as of March 31, 2004. The Company maintains an allowance for potential credit losses, but historically has not experienced any significant credit losses related to any individual customer or group of customers in any particular industry or geographic area.

SFAS No. 107, Disclosures about Fair Value of Financial Instruments, requires disclosure of an estimate of the fair value of certain financial instruments. The Company's financial instruments consist of cash equivalents, accounts receivable, acceptances payable, notes payable and potential obligations to non-qualified option holders. The estimated fair value of these financial instruments approximates their carrying value at March 31, 2004 and 2005. The estimated fair values have been determined through information obtained from market sources and management estimates.

In September 2000, the Emerging Issues Task Force issued EITF 00-19, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company's Own Stock, which requires freestanding contracts that are settled in a company's own stock, including common stock options and warrants, to be designated as an equity instrument, asset or a liability. Under the provisions of EITF 00-19, a contract designated as an asset or a liability must be carried at fair value, with any changes in fair value recorded in the results of operations. A contract designated as an equity instrument must be included within equity, and no fair value adjustments are required. In accordance with EITF 00-19, the Company determined that outstanding options granted to consultants as of March 31, 2003 should be designated as a liability in the Company's balance sheet.

All options granted to non-employees through March 31 2004 were for services rendered by the non-employees, had a life of ten years, had vesting periods ranging from immediate to four years and required delivery of registered shares upon exercise. The Company granted options at the same time the services were being performed, or at the time performance was complete. The Company granted options with exercise prices equal to the closing price of the Company's common stock on Nasdaq on the day of grant, with the exception of options granted to a marketing consultant that had an exercise price of $.01 per share.

During the fiscal years ended March 31, 2003 and 2004, the Company recorded the fair value of the options outstanding in the Company's results of operations, marking them to market using the Black-Scholes option-pricing model. The assumptions used in the Black-Scholes option-pricing model by the Company were as follows:

	March 31,
	2003	2004
Risk-free interest rate	1.09%-1.68%	.89%-.93%
Expected dividend yield	—	—
Expected lives	5 years	5 years
Expected volatility	65%-74%	65%-83%
Weighted average value of grants per share	$.64	$1.90

Effective March 31, 2004, the Company amended the non-qualified option agreements previously granted to non-employees. This amendment allowed the Company to settle its obligations to the holders by delivering unregistered shares upon exercise by the holders. As a result of this amendment, the options were characterized to be equity instruments, and accordingly, the fair market value of these options was transferred to the equity section of the Company's balance sheet as of March 31, 2004. In the fiscal year ended March 31, 2005, the Company accounted for these non-qualified options in accordance with the provisions of EITF 96-18, Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods and Services.

According to the provisions of EITF 96-18, the Company determines the fair value of options granted to non-employees using the Black-Scholes option-pricing model on the measurement date which is either the date a commitment for performance has been reached, or when performance has been completed, depending upon the facts and circumstances of the option. The fair value of the options valued at the measurement date is expensed over the vesting period of the options. This method approximates the same periods the expense would be recognized, had the Company paid cash for the services. The Company does not account for the fair value of options granted, in which the quantity and terms are known up front, prior to the measurement date, as services are not rendered prior to those dates. The Company accounts for the fair value of options granted, in which the quantity and terms are not known up front, when the services are performed.

During the fiscal year ended March 31, 2005, the Company granted options to purchase 150,000 shares to non-employees. The fair value measured at the option grant dates was approximately $371,000, determined using the Black-Scholes option-pricing model. The assumptions used in the Black-Scholes option-pricing model by the Company were as follows:

		March 31, 2005
Risk-free interest rate		.93%-1.36%
Expected dividend yield		—
Expected lives		5 years
Expected volatility		79%-83%
Weighted average value of grants per share		$3.81

Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) is presented in the consolidated statement of stockholders equity for all years presented.

The Company accounts for its employee stock-based compensation arrangements using the intrinsic value method under the provisions of Accounting Principles Board ("APB") Opinion No. 25, Accounting for Stock Issued to Employees, and Financial Interpretation No. ("FIN") 44. The Company does not recognize stock-based employee compensation cost when the options granted have an exercise price equal to, or greater than, the market value of the underlying common stock on the date of the grant. The Company does recognize stock-based employee compensation cost when the options granted have an exercise price less than the market value of the underlying common stock on the date of the grant.

In June 2003, the Company granted options to purchase 1,295,000 shares of common stock to certain of its employees at an exercise price of $1.04 per share. The fair market value of the common stock on the date of grant was $1.09 per share. As a result, the Company recognizes deferred compensation for the difference between the fair market value and the option price. This expense is recorded as the options vest. In the fiscal years ended March 31, 2005 and 2004, the Company recognized $13,187 and $16,484, respectively, of expense related to these options.

Had compensation expense for all stock option grants to employees been determined under the fair value method at the grant dates, consistent with the method prescribed by SFAS No. 123, the Company's net loss would have changed to the pro forma amounts indicated as follows:

	March 31,
	2003		2004		2005
Net loss—as reported	$	(1,707,095	)	$	(3,748,203	)	$	(2,505,303	)
Stock-based employee compensation—as reported		—			16,484			13,187
Pro forma stock-based employee compensation		(345,114	)		(283,218	)		(417,899	)

Net loss—pro forma	$	(2,052,209	)	$	(4,014,937	)	$	(2,910,015	)

Net loss per share—as reported	$	(.06	)	$	(.12	)	$	(.08	)
Stock-based employee compensation—as reported		—			—			—
Pro-forma stock-based employee compensation		(.02	)		(.01	)		(.01	)

Net loss per share—pro forma	$	(.08	)	$	(.13	)	$	(.09	)

The Company has computed the pro forma disclosures for stock options granted to employees after January 1, 1995 using the Black-Scholes option-pricing model prescribed by SFAS No. 123. The assumptions used during each of the three years ended March 31, 2005 were as follows.

Under the retroactive option, prior periods may be restated either as of the beginning of the year of adoption or for all periods presented. The prospective method requires that compensation expense be recorded for all unvested stock options and restricted stock at the beginning of the first quarter of adoption of SFAS 123R, while the retroactive method would record compensation expense for all unvested stock options and restricted stock beginning with the first period restated. The Company is evaluating the requirements of SFAS 123R and expects that the adoption of SFAS 123R may have a material impact on its consolidated results of operations and earnings per share. The Company has not yet determined the method of adoption or the effect of adopting SFAS 123R, and it has not determined whether the adoption will result in amounts that are similar to the current pro forma disclosures under SFAS 123.

In April 2002, the Company entered a financing arrangement with a bank that includes a revolving line of credit under which the Company may borrow up to $1,000,000, net of up to $250,000 of any outstanding letters of credit and bankers' acceptances. This arrangement expires on July 31, 2005, and is renewable upon mutual agreement. Borrowings under the arrangement bear interest at the bank's prime rate (5.75% at March 31, 2005) and must be fully cash collateralized. The arrangement also stipulates that when the Company achieves positive cash flow, as defined in the arrangement, the Company will be eligible to negotiate changes to these loan arrangements that may include changing the borrowing base for revolving loans, and the release of cash collateral. The Company is also subject to certain covenants, including the prohibition of paying cash dividends on its common stock. At March 31, 2005, the Company was in compliance with these covenants. At March 31, 2005, the Company had no bankers' acceptances payable, and had $67,200 reserved under the arrangement to cover a domestic letter of credit in favor of the landlord at the Company's Natick facility.

The Company accounts for income taxes under the liability method in accordance with SFAS No. 109, Accounting for Income Taxes. Under SFAS No. 109, deferred tax assets or liabilities are computed based on the differences between the financial statement and income tax bases of assets and liabilities as measured by the enacted tax rates.

The components of the net deferred tax asset recognized in the accompanying consolidated balance sheets with the approximate income tax effect of each type of temporary difference are as follows:

The Company has recorded a valuation allowance equal to its net deferred tax asset due to the uncertainty of realizing the benefit of this asset. The uncertainty is due to current and projected net losses.

At March 31, 2005, the Company had operating loss carryforwards available to offset future federal taxable income of approximately $51,000,000. These operating loss carryforwards expire at various dates through 2024 and are subject to review and possible adjustment by the Internal Revenue Service. At March 31, 2005, the Company had research and development tax credit carryforwards of approximately $402,000. These tax credits expire at various times through 2013 and are subject to review and possible adjustment by the Internal Revenue Service.

The Internal Revenue Code limits the amount of net operating loss carryforwards that companies may use in any one year in the event of certain cumulative changes in ownership over a three-year period.

On February 14, 2005, the Company sold, in a private equity placement, an aggregate of 3,703,702 shares of common stock at a price of $2.70 per share, resulting in gross proceeds of approximately $10,000,000. The per share price represented 91% of the closing price of the Company's common stock on the Nasdaq SmallCap Market at February 14, 2005. Two financial investors, who are independent of the Company, acquired approximately $8,000,000 of the common stock sold, and two stockholders, who are also directors and employees of the Company, (the "Insiders") acquired the remainder. In addition, as part of the transaction, the Company issued warrants to purchase an additional 1,103,704 shares of common stock to the investors and to the placement agent. The warrants are exercisable immediately over a period of five years at a price of $3.75 per share. The agreement does not require the Company to file any registration statement covering the resale of any of the common stock or warrants acquired by the investors in the transaction. However, the agreement does provide the investors with piggyback registration rights when and if the Company does file a registration statement.

On March 30, 2005, in response to the Nasdaq Stock Market informing the Company that it was in violation of certain Nasdaq Marketplace Rules regarding the sale of common stock to officers and directors at less than the closing bid price of the common stock, the Company and the two Insiders executed separate agreements to remediate the violation. One of the Insiders executed a contribution agreement providing for the payment of an additional amount in respect of the common stock purchased from the Company on February 14, 2005, thus bringing the price paid by him to $2.95 per share, the closing bid price of the common stock on February 14, 2005. The other Insider executed a rescission agreement, agreeing to rescind 31,387 shares of common stock purchased by him on February 14, 2005, thus increasing the cash price paid by him for the remaining shares to $2.95 per share. The Company recorded the contribution, received on April 7, 2005, as a subscription receivable in additional-paid-in-capital as of March 31, 2005. The Company recorded the rescission as a change in outstanding shares as of March 31, 2005.

On March 31, 2003, the Company completed a private equity placement with two stockholders who were also directors and employees of the Company. The Company sold an aggregate of 2,385,568 shares of common stock at a price of $0.6707 per share, which represented 67% of the average closing price of the Company's common stock on the Nasdaq SmallCap Market for the five trading days ended March 21, 2003. In addition, in April 2003, the Company sold 524,098 shares to three independent investors at the same share price. The Company received all the proceeds in exchange for newly issued shares of common stock. Gross proceeds to the Company totaled $1,600,000 and $351,513 in March and April 2003, respectively. The agreement did not require the Company to file any registration statement covering the resale of any of the common stock acquired by the investors in the transaction. However, the agreement does provide the investors with piggyback registration rights when and if the Company does file a registration statement. The transactions in March and April were treated as one transaction.

In each of these transactions, the discount was dictated by the level of interest of investors in the future prospects of the Company, and to the market for private placements generally. Both transactions were determined to be at fair market value by the Company's Board of Directors, and were approved in unanimous written consents. The approvals by the Board of Directors were made after their review of numerous factors, including the level of investor interest, the number of shares sold in each transaction compared to the average trading volume of the Company's stock on the Nasdaq SmallCap Market, and whether registration of the stock was a requirement of the investors.

The Company had a stock option plan (the "1990 Plan") under which it could grant key employees and consultants incentive and nonstatutory stock options at the fair value of the stock on the date of grant. Options became exercisable at varying dates ranging up to five years from the date of grant. The Board of Directors had authorized the issuance of options for the purchase of up to 4,375,000 shares of common stock under the 1990 Plan, of which 872,087 were retired as of the expiration date of the 1990 Plan.

During fiscal year 2001, the 1990 Plan expired and was replaced with the 2000 Stock Incentive Plan, (the "2000 Plan"). The terms of the 2000 Plan are substantially the same as the 1990 Plan. The Board of Directors has authorized the issuance of options for the purchase of up to 4,000,000 shares of common stock under the 2000 Plan, of which 726,358 shares remain available for future grant. The Company grants options to both employees and non-employee consultants.

A summary of the 2000 and 1990 Plans activity for employees for each of the three years ended March 31, 2005 is as follows:

The following table summarizes information about employee stock options outstanding and exercisable at March 31, 2005:

		Outstanding				Exercisable
Range of Prices Exercise		Number of Shares	Weighted Average Remaining Contractual Life (Years)	Weighted Average Exercise Price		Number of Shares	Weighted Average Exercise Price
$	.79-.93	255,000	9.65	$	.88	107,500	$	.86
	1.04-1.31	2,230,651	7.65		1.08	1,343,151		1.11
	1.50-1.82	201,500	5.48		1.59	167,750		1.55
	2.57-4.30	285,500	9.42		3.09	—		—

		2,972,651	7.84	$	1.29	1,618,401	$	1.14

The following table summarizes information about non-employee stock options outstanding and exercisable at March 31, 2005:

	Outstanding				Exercisable
Range of Prices Exercise	Number of Shares	Weighted Average Remaining Contractual Life (Years)	Weighted Average Exercise Price		Number of Shares	Weighted Average Exercise Price
$1.05–1.25	120,000	9.41	$	1.13	120,000	$	1.13
1.62–1.88	1,010,000	4.78		1.63	1,010,000		1.63
2.28–3.00	60,000	7.54		2.40	35,000		2.49
3.38–5.44	171,897	7.97		3.82	21,897		3.92

	1,361,897	5.72	$	1.90	1,186,897	$	1.65

Under the 1990 Plan and the 2000 Plan, there remain 1,638,247 and 2,696,301 shares of common stock, respectively, reserved for the exercise of stock options.

On August 16, 1993, the Company adopted the 1993 Director Option Plan (the "1993 Plan") under which it may grant up to 200,000 nonstatutory stock options to nonemployee directors of the Company at the fair value of the stock on the date of grant. Options become exercisable over a four-year period from the date of grant. The Company has reserved 200,000 shares of common stock for the exercise of stock options under the 1993 Plan. As of March 31, 2005, there were no shares available for future grant under the 1993 Plan.

	Number of Shares		Exercise Price Range		Weighted Average Exercise Price
Outstanding March 31, 2003	100,000		$	.97–11.63	$	3.28
Granted	—			—		—
Exercised	—			—		—
Canceled	(20,000	)		11.63		11.63

Outstanding March 31, 2004	80,000			.97–1.50		1.19
Granted	—			—		—
Exercised	—			—		—
Canceled	—			—		—

Outstanding March 31, 2005	80,000		$	.97–$1.50	$	1.19

Exercisable March 31, 2003	64,000		$	.97-$11.63	$	4.51

Exercisable March 31, 2004	56,000		$	.97–$1.50	$	1.24

Exercisable March 31, 2005	68,000		$	.97–$1.50	$	1.21

The following table summarizes information about director stock options outstanding and exercisable at March 31, 2005:

	Outstanding				Exercisable
Range of Prices Exercise	Number of Shares	Weighted Average Remaining Contractual Life (Years)	Weighted Average Exercise Price		Number of Shares	Weighted Average Exercise Price
$.97–1.00	40,000	6.38	$	.99	32,000	$	.99
1.30	20,000	6.38		1.30	16,000		1.30
1.50	20,000	2.37		1.50	20,000		1.50

	80,000	5.38	$	1.19	68,000	$	1.21

In July 2003, the Company adopted, and the stockholders approved, a 2003 Director Option Plan (the "2003 Plan"). The terms of the 2003 Plan include automatic grants of 4,000 shares to each outside director on each date on which an annual meeting of the stockholders of the Company is held, provided that such outside director does not hold on such date any outstanding options to purchase common stock of the Company's 1993 Plan, which options are not fully exercisable. If the Company's annual meeting of stockholders is held in July of each year, the Company will grant options to purchase 4,000 shares in 2005 and 12,000 shares in 2006 and 2007. The Company has reserved 200,000 shares of common stock for grant under the 2003 Plan.

The Company has an agreement, as amended, with an independent consultant to provide services regarding the design, development and clinical testing of ENT products for the ENT market, and trans-nasal esophagoscopy ("TNE") products for the GI market. The agreement provides the independent consultant with compensation in the form of both cash and stock options. Cash compensation totaled $48,000, paid in equal installments over six months. The agreement provides the independent consultant may earn up to 500,000 options to purchase the Company's common stock, if various performance criteria are met. The agreement requires all options be granted at fair market value as of the date of grant, and that all option grants vest over two years equally on each of the first and second anniversaries of the date of grant.

In January 2003, the Company began the cash payments, and made an initial option grant to the consultant to purchase 100,000 shares of the Company's common stock. The value of that option grant was approximately $69,000, calculated using the Black-Scholes option-pricing model. The cash payments were expensed as they were paid. The initial option grant was recorded as an expense in the consolidated statement of operations for the fiscal year ended March 31, 2003, as the independent consultant was not required to perform any additional services to earn the option.

During the fiscal year ended March 31, 2004, in accordance with an amendment to the agreement, the Company made another option grant to the consultant to purchase 50,000 shares of the Company's common stock. The value of that option grant was approximately $88,000, calculated using the Black-Scholes option-pricing model. The full value of the option was recorded as an expense in the consolidated statement of operations for the fiscal year ended March 31, 2004, as the independent consultant was not required to perform any additional services to earn the option.

In April 2004, according to the agreement, the Company granted the independent consultant an option to purchase 100,000 shares of the Company's common stock. The independent consultant earned this grant pursuant to the terms of the agreement that require the Company to grant an option of up to 100,000 shares, depending upon the incremental sales of ENT products to domestic customers for the fiscal year ended March 31, 2004, compared to the prior fiscal year. The value of that option was approximately $242,000, calculated using the Black-Scholes option-pricing model, and is being recorded as an expense in the Company's consolidated statements of operations over the two-year vesting period. During the fiscal year ended March 31, 2005, the Company recorded approximately $121,000 of expense related to this option.

In July 2004, according to the amendment in the agreement, the Company made an additional grant of options to the independent consultant to purchase 50,000 shares of the Company's common stock, as the Company had not established a domestic distribution channel with a third party for its TNE products to the GI market by July 1, 2004. The value of that option was approximately $129,000, calculated using the Black-Scholes option-pricing model, and is being recorded as an expense in the Company's consolidated statements of operations over the two-year vesting period. During the fiscal year ended March 31, 2005, the Company recorded approximately $48,000 of expense related to this option. The assumptions used in the Black-Scholes option-pricing model by the Company for each of these option grants were as follows:

	January 2003		January 2004		April 2004		July 2004
Risk-free interest rate		1.09	%		.89	%		.93	%		1.36	%
Expected dividend yield		—			—			—			—
Expected lives		5 years			5 years			5 years			5 years
Expected volatility		65	%		75	%		83	%		79	%
Value of grants per share	$	1.05		$	2.28		$	3.69		$	4.05

The agreement requires the Company to grant additional options to the consultant, depending upon the incremental increase in sales of ENT products and TNE products in the fiscal year ended March 31, 2005, compared to the fiscal year ended March 31, 2004. Each additional option grant will be up to 100,000 shares. The independent consultant did not earn any option grants related to these terms, and there are no further grants required under the terms of the agreement.

The Company rents its facilities in Natick, MA and Orangeburg, NY under various agreements due to expire on October 31, 2006 and August 31, 2010, respectively. The Company also leases some office equipment under leases that expire in 2007. Rental expense charged to operations under leases from nonrelated parties was approximately $307,000, $302,000 and $392,000 for the years ended March 31, 2003, 2004 and 2005, respectively. Approximate future minimum lease commitments under all operating leases are as follows:

Year Ending March 31,	Commitment
2006	$	401,000
2007		317,000
2008		203,000
2009		199,000
2010 and after		233,000

	$	1,353,000

The Company has a 401(k) plan (the "Plan") whereby employees may contribute a certain percentage of their annual compensation, up to a defined maximum. The Company may, but is not obligated to, make a matching contribution up to a certain percentage of each employee's contribution. During the years ended March 31, 2003, 2004 and 2005, the Company recorded matching contributions of approximately $34,000, $38,000 and $42,000, respectively, relating to the Plan.

SFAS No. 131, Disclosures about Segments of an Enterprise and Related Information, establishes standards for reporting information about operating segments and related disclosures about products and services, geographic areas and major customers.

The Company has determined it has three reportable segments—medical, industrial and corporate. The medical segment designs, manufactures and sells endosheaths and sells endoscopes to users in the health care industry. The industrial segment designs, manufactures and sells borescopes to a variety of users, primarily in the aircraft maintenance industry. In addition, the industrial segment manufactures and repairs endoscopes for the medical segment. The corporate segment consists of certain administrative expenses applicable to the Company as a whole.

The accounting policies of the segments are described in the summary of significant accounting policies. The Company evaluates segment performance based upon operating income. Identifiable assets are those used directly in the operations of each segment. Corporate assets include cash, marketable securities and the investment in Vision Sciences Ltd. Data regarding management's view of the Company's segments is provided in the following tables.

The following table identifies sales by geographic region. Sales are attributable to geographic regions based upon the location of customers.

	Fiscal Years Ended March 31,
Geographic Region	Fiscal Years Ended March 31,
Geographic Region	2003		2004		2005
Asia Pacific	$	551,680	$	493,732	$	718,379
Canada		145,301		196,538		95,805
Europe		1,197,643		2,066,586		2,138,898
Middle East and Africa		9,047		60,379		256,515
Central & South America		186,243		163,482		160,416
United States		4,339,728		6,946,409		6,955,960

Total	$	6,429,642	$	9,927,126	$	10,325,973

For the fiscal year ended March 31, 2003, no customer accounted for 10% or more of consolidated net sales. For the fiscal year ended March 31, 2004, two customers accounted for 30% and 10%, respectively, of consolidated net sales. For the fiscal year ended March 31, 2005, one customer accounted for 35% of consolidated net sales.

	March 31,
	2004		2005
Accrued payroll and related expenses	$	775,034	$	776,926
Accrued other		195,721		436,651

	$	970,755	$	1,213,577

Included in accrued payroll and related expenses is approximately $419,000 and $384,000 at March 31, 2004 and 2005, respectively, owed to an employee/director of the Company, whose salary was accrued but not paid to him from October 1995 through December 2001. The employee/director resumed receiving his salary in cash in January 2002.

The following table contains certain selected quarterly financial data for the fiscal years ended March 31, 2004 and 2005.

	(a)	(b)		(c)
Plan category	Number of securities to be issued upon exercise of outstanding options, warrants and rights (1)(2)	Weighted-average exercise price of outstanding options, warrants and rights		Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) (1)(2)
Equity compensation plans approved by security holders	4,414,548	$	1.48	926,358
Equity compensation plans not approved by security holders (3)	500,000	$	0	0

Total	4,914,548	$	1.48	926,358

	Year Ended March 31,
	2001			2002			2003			2004			2005
	(in thousands, except per share data)
Statement of Operations Data:
Net sales	$	7,209		$	6,713		$	6,430		$	9,927		$	10,326
Gross profit		2,560			2,222			1,667			3,771			2,944
Loss from operations		(1,173	)		(1,181	)		(1,759	)		(3,794	)		(2,558	)
Net loss		(1,291	)		(1,895	)		(1,707	)		(3,748	)		(2,505	)
Net loss per share		(.06	)		(.07	)		(.06	)		(.12	)		(.08	)
Balance Sheet Data:
Cash and cash equivalents	$	3,812		$	3,142		$	2,869		$	2,715		$	9,869
Total assets		7,195			6,000			5,447			6,729			14,748
Total liabilities		1,969			1,878			1,311			1,763			1,907
Stockholders' equity		5,226			4,122			4,136			4,966			12,841

		VISION-SCIENCES, INC.
DATE: JUNE 29, 2005		By:	/s/ RON HADANI Ron Hadani President, Chief Executive Officer

			2004			2005
Assets
Current Assets:
	Cash and cash equivalents		$	2,714,941		$	9,868,586
	Accounts receivable, net of allowance for doubtful accounts of $52,800 and $70,097 in 2004 and 2005, respectively			1,683,459			1,662,486
	Inventories, net			1,352,716			1,876,824
	Prepaid expenses and other current assets			62,182			61,964

		Total current assets		5,813,298			13,469,860

Property and Equipment, at cost:
	Machinery and equipment			3,623,854			4,427,047
	Furniture and fixtures			212,002			242,406
	Leasehold improvements			473,411			573,780

				4,309,267			5,243,233
	Less—Accumulated depreciation and amortization			3,728,242			4,040,060

				581,025			1,203,173

Advance to 3BY Ltd.				267,500			—

Other Assets, net of accumulated amortization of $47,428 and $53,815 in 2004 and 2005, respectively				66,751			74,816

		Total assets	$	6,728,574		$	14,747,849

Liabilities and Stockholders' Equity
Current Liabilities:
	Acceptances payable to a bank		$	51,766		$	—
	Current portion of note payable			17,495			24,431
	Accounts payable			681,998			637,408
	Accrued expenses			970,755			1,213,577

		Total current liabilities		1,722,014			1,875,416

Long term Portion of Note Payable				40,614			31,089

Commitments (Note 6)
Stockholders' Equity:
	Preferred stock, $.01 par value—
		Authorized—5,000,000 shares Issued and outstanding—none		—			—
	Common stock, $.01 par value—
		Authorized—50,000,000 shares Issued and outstanding—30,687,963 shares and 34,998,877 shares at March 31, 2004 and 2005, respectively		306,879			349,988
	Additional paid-in capital			64,649,956			74,987,548
	Accumulated deficit			(59,990,889	)		(62,496,192	)

		Total stockholders' equity		4,965,946			12,841,344

		Total liabilities and stockholders' equity	$	6,728,574		$	14,747,849

		2003			2004			2005
Net Sales		$	6,429,642		$	9,927,126		$	10,325,973
Cost of Sales			4,762,412			6,155,676			7,382,431

	Gross profit		1,667,230			3,771,450			2,943,542
Selling, General and Administrative Expenses (1)			3,115,008			3,478,375			3,897,351
Research and Development Expenses (1)			426,210			688,627			1,421,577
Stock-based compensation charge (credit)			(115,009	)		3,398,036			182,579

	Loss from operations		(1,758,979	)		(3,793,588	)		(2,557,965	)
Interest Income			37,652			30,387			46,316
Interest Expense			(724	)		—			(4,971	)
Other Income, net			14,956			14,998			11,317

	Net loss	$	(1,707,095	)	$	(3,748,203	)	$	(2,505,303	)

Basic and Diluted Net Loss per Common Share		$	(.06	)	$	(.12	)	$	(.08	)

Shares Used in Computing Basic and Diluted Net Loss per Common Share			27,202,051			30,213,223			31,447,332

(1) Excludes non-cash stock-based compensation charge (credit) as follows:
Selling, General and Administrative Expenses		$	75,588		$	814,992		$	182,142
Research and Development Expenses			(190,597	)		2,583,044			437

		$	(115,009	)	$	3,398,036		$	182,579

		Common Stock
		Number of Shares	$.01 Par Value		Additional Paid-in Capital		Accumulated Deficit			Total Stockholders' Equity			Total Comprehensive Loss
Balance, March 31, 2002		27,105,355	$	271,052	$	58,386,502	$	(54,535,591	)	$	4,121,963		$
	Sale of common stock, net	2,385,568		23,856		1,569,489		—			1,593,345
	Exercise of incentive stock options	16,000		160		19,567		—			19,727
	Exercise of non-qualified stock options	81,357		814		107,372		—			108,186
	Net loss	—		—		—		(1,707,095	)		(1,707,095	)		(1,707,095	)

Total Comprehensive Loss														(1,707,095	)

Balance, March 31, 2003		29,588,280		295,882		60,082,930		(56,242,686	)		4,136,126
	Sale of common stock, net	524,098		5,241		323,771					329,012
	Exercise of incentive stock options	485,800		4,858		574,596					579,454
	Exercise of non-qualified stock options	89,785		898		68,975					69,873
	Compensation expense related to employee non-qualified stock options					16,484					16,484
	Compensation expense related to non- qualified stock option exercises					180,801					180,801
	Conversion of non-qualified stock options to non-employees to equity instruments					3,402,399					3,402,399
	Net loss	—		—		—		(3,748,203	)		(3,748,203	)		(3,748,203	)

Total Comprehensive Loss														(3,748,203	)

Balance, March 31, 2004		30,687,963		306,879		64,649,956		(59,990,889	)		4,965,946
	Sale of common stock, net	3,672,315		36,723		9,407,760					9,444,483
	Exercise of incentive stock options	456,449		4,564		522,746					527,310
	Exercise of non-qualified stock options	182,150		1,822		224,507					226,329
	Compensation expense related to employee non-qualified stock options					13,187					13,187
	Compensation expense related to non-employee non-qualified stock options					169,392					169,392
	Net loss	—		—		—		(2,505,303	)		(2,505,303	)		(2,505,303	)

Total Comprehensive Loss													$	(2,505,303	)

Balance, March 31, 2005		34,998,877	$	349,988	$	74,987,548	$	(62,496,192	)	$	12,841,344

				2003			2004			2005
Cash Flows from Operating Activities:
	Net loss			$	(1,707,095	)	$	(3,748,203	)	$	(2,505,303	)
	Adjustments to reconcile net loss to net cash used in operating activities—
		Depreciation and amortization			238,736			204,606			318,205
		Stock-based compensation charge (credit) from non-qualified stock options			(115,009	)		3,398,036			182,579
		Changes in assets and liabilities—
			Accounts receivable		97,866			(946,748	)		20,973
			Inventories		32,809			(192,344	)		(524,108	)
			Prepaid expenses and other current assets		25,819			(11,069	)		218
			Accounts payable		7,582			387,686			(44,590	)
			Accrued expenses		(299,017	)		166,616			242,822

		Net cash used in operating activities			(1,718,309	)		(741,420	)		(2,309,204	)

Cash Flows from Investing Activities:
		Decrease in marketable securities			126,373			125,072			—
		Purchase of property and equipment			(114,496	)		(239,614	)		(666,466	)
		Advances to 3BY Ltd.			—			(267,500	)		—
		Decrease (Increase) in other assets			—			16,667			(14,452	)

			Net cash provided by (used in) investing activities		11,877			(365,375	)		(680,918	)

Cash Flows from Financing Activities:
		Proceeds from (payments of) acceptances payable to a bank, net			(32,605	)		41,145			(51,766	)
		(Payments of) proceeds from note payable, net			(23,989	)		58,109			(2,589	)
		Proceeds from the sale of common stock, net			1,593,345			329,012			9,444,483
		Proceeds from exercise of stock options			23,460			649,327			753,639

			Net cash provided by financing activities		1,560,211			1,077,593			10,143,767

Net Increase (Decrease) in Cash and Cash Equivalents					(146,221	)		(29,202	)		7,153,645
Cash and Cash Equivalents, beginning of year					2,890,364			2,744,143			2,714,941

Cash and Cash Equivalents, end of year				$	2,744,143		$	2,714,941		$	9,868,586

Supplemental Disclosure of Non-Cash Investing and Financing Activities:
		Manufacturing equipment acquired in exchange for advance to 3BY Ltd.		$	—		$	—		$	267,500

		Computer equipment acquired in exchange for note payable		$	—		$	58,109		$	—

		Conversion of potential obligation to non-qualified option holders		$	—		$	3,402,397		$	—

Supplemental Disclosure of Cash Flow Information:
		Cash paid during the year for interest		$	724		$	—		$	4,971

		March 31,
		2004			2005
Net operating loss carryforwards		$	19,089,000		$	20,424,000
Nondeductible reserves			397,000			522,000
Research and development credit carryforwards			531,000			531,000
Other temporary differences			1,604,000			1,067,000
Depreciation			45,000			60,000

			21,666,000			22,604,000
Less—Valuation allowance			(21,666,000	)		(22,604,000	)

	Net deferred tax asset	$	—		$	—

	Number Of Shares		Exercise Price Range		Weighted Average Exercise Price
Outstanding March 31, 2002	1,834,550			1.05-7.25		1.64
Granted	746,000			.79-1.05		.97
Exercised	(16,000	)		1.06-1.31		1.23
Canceled	(76,500	)		.89- .50		1.25

Outstanding March 31, 2003	2,488,050			.79-7.25		1.46
Granted	1,360,000			.93-1.82		1.07
Exercised	(485,800	)		.79-1.63		1.19
Canceled	(146,500	)		1.19-7.25		6.36

Outstanding March 31, 2004	3,215,750			.79-1.82		1.11
Granted	325,500			2.57-4.30		3.20
Exercised	(491,099	)		.79-1.50		1.16
Canceled	(77,500	)		.89-4.00		2.52

Outstanding March 31, 2005	2,972,651		$	.79-$4.30	$	1.29

Exercisable, March 31, 2003	1,760,800		$	1.06-$7.50	$	1.65

Exercisable, March 31, 2004	1,619,000		$	.79-$1.82	$	1.40

Exercisable, March 31, 2005	1,618,401		$	.79-$1.82	$	1.14

	Number Of Shares		Exercise Price Range		Weighted Average Exercise Price
Outstanding March 31, 2002	1,375,819			.01-7.50		1.89
Granted	164,570			.01-1.05		.64
Exercised	(77,357	)		.01		.01
Canceled	—			.89-1.50		1.25

Outstanding March 31, 2003	1,463,032			.01-7.50		1.85
Granted	70,000			.94-2.28		1.90
Exercised	(89,785	)		.01-1.25		.78
Canceled	(58,333	)		7.50		7.50

Outstanding March 31, 2004	1,384,914			.94-5.50		1.68
Granted	150,000			3.69-4.05		3.81
Exercised	(147,500	)		.94-3.00		1.24
Canceled	(25,517	)		5.44-5.50		5.49

Outstanding March 31, 2005	1,361,897		$	1.05-$5.44	$	1.90

Exercisable, March 31, 2003	1,363,032		$	.01-$7.50	$	1.91

Exercisable, March 31, 2004	1,279,914		$	.94-$5.50	$	1.69

Exercisable, March 31, 2005	1,186,897		$	1.05-$5.44	$	1.65

Fiscal Year Ended March 31,	Medical			Industrial			Corporate			Adjustments			Total
2003
Sales to external customers	$	3,775,066		$	2,654,576		$	—		$	—		$	6,429,642
Intersegment sales		—			666,488			—			(666,488	)		—
Operating (loss) income		(1,001,487	)		(165,496	)		(591,996	)		—			(1,758,979	)
Interest income (expense), net		—			(724	)		37,652			—			36,928
Depreciation and amortization		198,000			40,736			—			—			238,736
Other significant non-cash items:
Stock-based compensation (credit)		—			—			(115,009	)		—			(115,009	)
Total assets		1,905,604			990,385			2,961,189			(410,332	)		5,446,846
Expenditures for fixed assets		82,954			31,542			—			—			114,496
2004
Sales to external customers	$	6,700,606		$	3,226,520		$	—		$	—		$	9,927,126
Intersegment sales		—			1,884,389			—			(1,884,389	)		—
Operating (loss) income		446,634			263,756			(4,503,978	)		—			(3,793,588	)
Interest income (expense)		—			—			30,387			—			30,387
Depreciation and amortization		164,211			40,395			—			—			204,606
Other significant non-cash items:
Stock-based compensation (credit)		937			312			3,396,787						3,398,036
Total assets		2,563,950			1,307,458			2,806,915			50,251			6,728,574
Expenditures for fixed assets		225,442			14,172			—			—			239,614
2005
Sales to external customers	$	7,237,221		$	3,088,752		$	—		$	—		$	10,325,973
Intersegment sales		—			2,736,615			—			(2,736,615	)		—
Operating (loss) income		(1,626,180	)		293,485			(1,225,270	)		—			(2,557,965	)
Interest income (expense), net		—			—			41,345			—			41,345
Depreciation and amortization		260,775			51,411			6,019			—			318,205
Other significant non-cash items:
Stock-based compensation (credit)		170,142			250			12,187			—			182,579
Total assets		3,380,360			1,655,084			9,954,541			(242,136	)		14,747,849
Expenditures for fixed assets		630,596			35,870			—			—			666,466

Description (rounded)			Balance, Beginning of Year		Charged to Costs and Expenses		Write-offs		Balance, End of Year
Deducted from Assets Accounts:
	Allowance for doubtful accounts—
		Year ended March 31, 2003	$	77,000	$	4,000	$	4,000	$	77,000
		Year ended March 31, 2004		77,000		4,000		28,000		53,000
		Year ended March 31, 2005		53,000		22,000		5,000		70,000
	Inventory reserves
		Year ended March 31, 2003	$	1,063,000	$	—	$	24,000	$	1,039,000
		Year ended March 31, 2004		1,039,000		—		107,000		932,000
		Year ended March 31, 2005		932,000		116,000		197,000		851,000

	(in thousands, except per share data)
	Quarterly Operating Results
	Q1 2004			Q2 2004			Q3 2004		Q4 2004
Statement of Operations Data:
Net sales	$	1,960		$	2,107		$	2,718	$	3,142
Gross profit		757			802			892		1,320
Income (loss) from operations		(329	)		(849	)		17		(2,632	)
Net income (loss)		(317	)		(839	)		27		(2,619	)
Net income (loss) per share		(.01	)		(.03	)		—		(.08	)

	Q1 2005			Q2 2005			Q3 2005			Q4 2005
Net sales	$	2,777		$	2,031		$	2,827		$	2,691
Gross profit		1,082			251			787			823
Loss from operations		(287	)		(936	)		(795	)		(540	)
Net loss		(276	)		(930	)		(786	)		(513	)
Net loss per share		(.01	)		(.03	)		(.02	)		(.02	)

Exhibit		Description of Exhibit
3.1.(1)		Amended and Restated Certificate of Incorporation of the Company, as amended to date
3.2.(2)		By-laws, as amended to date
*10.1.(3)		1990 Stock Option Plan, as amended
*10.2.(3)		1993 Director Option Plan
*10.3.(4)		2000 Stock Incentive Plan
*10.4.(2)		Vision-Sciences, Inc. 401(k) Plan, as amended
*10.5.(2)		Form of Vision-Sciences, Inc. Invention, Non-Disclosure and Non-Competition Agreement for employees
10.6.(14)		Letter Agreement between the Company and Ron Hadani dated January 24, 2003
10.7.(5)		Letter Agreement between the Company and James A. Tracy dated July 18, 1997
10.8.(10)		Letter Agreement between the Company and Thomas M. Olmstead dated October 1, 2001
10.9.(2)		Registration Rights Agreement dated as of February 28, 1992 among the Registrant and the persons listed therein
10.10.(1)		Piggyback Registration Rights Agreement, dated January 2, 2001, between the Company and the individuals and entities listed therein
10.11.(11)		Supply Agreement dated March 16, 1992 between the Registrant and Pentax Corporation (formerly known as Asahi Optical Co., Ltd.) and amendment dated October 1, 2002
**10.12.(6)		Investment Agreement dated as of August 6, 1998 among Vision-Sciences, Inc., 3DV Systems Ltd. and RDC Rafael Development Corporation Ltd.
10.13.(2)		Non-Exclusive License Agreement among Opielab, Inc., O.S. Limited Partnership and Pentax Corporation (formerly Asahi Optical Co., Ltd.) dated September 28, 1988
10.14.(7)		License Agreement between Vision-Sciences, Inc. and Advanced Polymers, Inc. dated June 10, 1993
10.15.(8)		Amendment to License Agreement between Vision-Sciences, Inc. and Advanced Polymers, Inc. dated April 5, 1994
10.16.(9)		Amendment to License Agreement between Vision-Sciences, Inc. and Advanced Polymers, Inc. dated April 5, 1995
10.17.(9)		Amendment to License Agreement between Vision-Sciences, Inc. and Advanced Polymers, Inc. dated April 5, 1996
**10.18.(6)		License and Manufacturing Agreement dated as of August 6, 1998 between Vision-Sciences, Inc. and 3DV Systems Ltd.
**10.19.(6)		License Agreement dated as of August 6, 1998 between Vision-Sciences, Inc. and Pentax Corporation (formerly Asahi Optical Co., Ltd.)
10.20.(9)		Lease between Paul D. McKeon, Trustee of 14 Burr Street Realty Trust and Vision-Sciences, Inc. dated April 23, 1993
10.21.(4)		Agreement of Lease between 30 Ramland Road LLC and Vision-Sciences, Inc. dated as of March 23, 2000
**10.22.(6)		Memorandum of Understanding dated August 6, 1998 between Vision-Sciences, Inc. and Imagineering, Ltd.
10.22.(10)		Business Loan Agreement and Commercial Pledge and Security Agreement among Vision-Sciences, Inc., Machida, Inc. and The First National Bank of Boston dated January 24, 1995
10.23.(10)		Extension to Business Loan Agreement and Commercial Pledge and Security Agreement among Vision-Sciences, Inc., Machida, Inc. and The First National Bank of Boston dated January 7, 2002

10.24.(10)		Loan Agreement between Vision-Sciences, Inc. and Citizens Bank of Massachusetts dated April 30, 2002
10.25.(10)		Pledge Agreement between Vision-Sciences, Inc. and Citizens Bank of Massachusetts dated April 30, 2002
10.26.(12)		Exclusive Distribution Agreement between the Company and Medtronic Xomed, Inc. dated August 6, 2003
**10.27.(16)		Exclusive Distribution Agreement between the Company and Medtronic USA, Inc. dated December 29, 2004
10.28.(13)		Contract Manufacturing Agreement between the Company and Three BY Ltd. dated June 25, 2003
10.29.(13)		Loan Agreement between the Company and Three BY Ltd. dated June 25, 2003
10.30.(13)		Pledge Agreement between the Company and Three BY Ltd. dated June 25, 2003
10.31.(15)		Securities Purchase Agreement between the Company and each purchaser identified on the signature page thereto dated February 14, 2005
10.32.(15)		Form of Warrant of the Company
21.1.		Subsidiaries of the Company
23.1.		Consent of BDO Seidman, LLP
31.1.		Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended
31.2		Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended
32		Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002